



Association Between Hepatitis B Virus and Chronic Kidney Disease: a Systematic Review and Meta-analysis

Fabrizio Fabrizi,* Francesca M. Donato,** Piergiorgio Messa*

* Division of Nephrology, ** Division of Gastroenterology, Maggiore Hospital and IRCCS Foundation, Milano, Italy.

ABSTRACT

Background. Hepatitis B virus infection and chronic kidney disease are prevalent and remain a major public health problem worldwide. It remains unclear how infection with hepatitis B virus impacts on the development and progression of chronic kidney disease. **Aim.** To evaluate the effect of infection with HBV on the risk of chronic kidney disease in the general population. **Material and methods.** We conducted a systematic review of the published medical literature to determine if hepatitis B infection is associated with increased likelihood of chronic kidney disease. We used the random effects model of DerSimonian and Laird to generate a summary estimate of the relative risk for chronic kidney disease (defined by reduced glomerular filtration rate and/or detectable proteinuria) with hepatitis B virus across the published studies. Meta-regression and stratified analysis were also conducted. **Results.** We identified 16 studies ($n = 394,664$ patients) and separate meta-analyses were performed according to the outcome. The subset of longitudinal studies addressing ESRD ($n = 2$; $n = 91,656$) gave a pooled aHR 3.87 (95% CI, 1.48; 6.25, $P < 0.0001$) among HBV-infected patients and no heterogeneity was recorded. In meta-regression, we noted the impact of male ($P = 0.006$) and duration of follow-up ($P = 0.007$) upon the adjusted hazard ratio of incidence of chronic kidney disease (including end-stage renal disease). No relationship occurred between HBV positive status and prevalent chronic disease ($n = 7$, $n = 109,889$ unique patients); adjusted odds ratio, were 1.07 (95% CI, 0.89; 1.25) and 0.93 (95% CI, 0.76; 1.10), respectively. **Conclusions.** HBV infection is possibly associated with a risk of developing reduced glomerular filtration rate in the general population; no link between HBV sero-positive status and frequency of chronic kidney disease or proteinuria was noted in cross-sectional surveys.

Key words. Hepatitis B virus. Chronic kidney disease. Glomerular filtration rate. Proteinuria. Meta-analysis.

INTRODUCTION

Chronic kidney disease is a growing public health issue worldwide. The prevalence of chronic kidney disease, defined by a reduction in glomerular filtration rate and/or increased urinary albumin excretion, exceeds 10% of the adult general population, according to some population-based studies.¹ Conventional risk factors for chronic kidney disease include demographics (aging, gender), lifestyles (smoking, alcohol intake, physical exercise), and co-morbidities (diabetes mellitus, arterial hypertension, anaemia, overweight);² also, chronic hepatitis C virus infection has been recently associated to the risk of chronic kidney disease in the general population³ and among HIV-infected individuals.⁴ However, the mechanisms

underlying the current frequency of chronic kidney disease in the general population of developed world remain unclear.

Hepatitis B virus (HBV) infection is an important cause of liver disease and cancer and infects about 400 million individuals worldwide. In addition to its effects in the liver, extra-hepatic manifestations may be observed in up to 20% of patients infected with HBV, in both acute and chronic infections. Manifestations related to HBV include mixed cryoglobulinemia vasculitis, polyarteritis nodosa, and renal disease.⁵ The association between HBV infection and glomerular disease has been already explored by various authors; the most common type of HBV-related glomerulonephritis is membranous nephropathy, particularly in the Asian

continent.⁶ Also, chronic hepatitis B serum promotes apoptotic damage in human renal tubular cells.⁷ Either insulin resistance⁸ and oxidative stress⁹ have been related to HBV infection; both conditions may contribute to renal injury.

Whether HBV-infected individuals have increased risk for development and progression of chronic kidney disease has not been appropriately investigated. The aim of this study was to review the available evidence on the link between HBV infection and frequency of chronic kidney disease (low estimated glomerular filtration rate and/or detectable proteinuria) at population-based level by performing a systematic review of the literature with a meta-analysis of clinical observational studies.

MATERIAL AND METHODS

This work is in agreement with the Preferred Reporting Items for Systematic reviews and Meta-Analyses statement¹⁰ (Supplementary file 1).

Search strategy and data extraction

Two authors (F.F., and F.M. D.) independently reviewed English-language citations from the national Library of Medicine's Medline database from 1970 through July 1, 2015. Data on HBsAg status were not available before 1970, when the first assay for HBsAg was manufactured. We conducted our search by four Medline databases engines (Embase, Grateful Med, Ovid, and PubMed). Our Medline search was limited to human studies. We applied the following algorithm in medical subject heading and in free text words: ("HEPATITIS B" or "HEPATITIS B VIRUS INFECTION" or "HBsAg POSITIVE STATUS" or "HBc ANTIBODY POSITIVE STATUS") and ("CHRONIC KIDNEY DISEASE" or "CKD" or "END-STAGE RENAL DISEASE" or "ESRD" or "LOW GLOMERULAR FILTRATION RATE" or "RENAL IMPAIRMENT" or "RENAL INSUFFICIENCY" or "RENAL FAILURE" or "PROTEINURIA" or "GLOMERULONEPHRITIS") and ("RELATIVE RISK" or "RISK RATIO" or "RR" or "ODDS RATIO" or "OR" or "HAZARD RATIO" or "HR" or "INCIDENCE"). An additional search was performed with electronic searches of the Cochrane Library; manual searches of selected specialty journals were done to identify all pertinent literature. Reference lists from qualitative topic reviews and published clinical studies were also searched. It was previously demonstrated that a Medline search alone might not be sensitive enough.¹¹ Data on study design, study period, patient characteristics, HBV prevalence, and kidney disease outcomes were abstracted. Authors of selected papers were contacted to obtain missing data and only data

from individuals with known HBV status were included in the meta-analysis. Consensus was achieved for all data. Studies were compared to eliminate duplicate reports for the same patients, which included contact with investigators when necessary. Eligibility and exclusion criteria were pre-specified. Our search was limited to human studies that were published in the English literature.

Inclusion criteria

Studies were included if they met the following inclusion criteria:

- They presented original data from cohort and cross-sectional studies.
- The outcome of interest was clearly defined as incidence or prevalence of chronic kidney disease, i.e., reduced glomerular filtration rate and/or detectable proteinuria in the adult general population according to HBV serological status; and
- They provided adjusted risk estimates and their confidence intervals.

We considered both case-control studies and cohort studies as eligible for inclusion in the analysis. We included studies where the diagnosis of HBV infection was done by testing for HBsAg in serum and/or HBc antibody. Information on HBV serological status was collected at the time of enrolment. If data on the same population were duplicated in more than one study, the most recent study was included in the analysis.

Ineligible studies

Studies were excluded if they reported inadequate data on the association between chronic kidney disease and HBV sero-positive status (e.g., incomplete information on HBV status or renal outcomes). Unpublished studies, studies that were only published in abstract form or as interim reports were excluded; letters and review articles were not considered for this systematic review.

Quality assessment

The quality of the 13 studies was appraised using a scale adapted from the 'Newcastle/Ottawa Scale (NOS)'.¹² The Newcastle-Ottawa scale is a scoring system that assesses every aspect of an observational epidemiologic study from a methodological point of view. When a study included relevant information that could be associated with the NOS, one point was added. Seven items in cross-sectional studies and eight items in cohort and case-control studies that could be related to the NOS were identified. There-

fore, cross-sectional studies assigned 8-10, 6-7, 4-5, or 0-3 points (stars) were evaluated as very good, good, satisfactory or unsatisfactory studies, respectively. Similarly, cohort/case-control studies with 7-9, 5-6, 4 and 0-3 points (stars) were identified as very good, good, satisfactory or unsatisfactory, respectively. We carried out subgroup analyses based on those studies provided with very good quality. Data extraction and quality scoring were performed independently by two reviewers (F.F. and F.M. D.) and the results were merged by consensus. The complete protocol for quality scoring is available on-line (Supplementary file 2).

Outcomes measures

We performed separate meta-analyses according to the outcome. One meta-analysis included longitudinal studies addressing the incidence of chronic kidney disease or end-stage renal disease; and another regarded cohort studies assessing the prevalence of CKD. An additional meta-analysis was performed for prevalent proteinuria. Staging of chronic kidney disease was categorized according to the Kidney Disease Outcomes Quality Initiative (K/DOQI) definition, and estimated glomerular filtration rate was calculated using the 4-variable MDRD equation.¹³ The primary end point was to provide adjusted estimates of the risk (and 95% CIs) of incidence (or prevalence) of chronic kidney disease in the general population according to HBV serological status. Multivariate analysis was made to estimate the independent effect of HBV positive status on the frequency of chronic kidney disease after adjustment for potential confounders (covariates) (e.g., age, gender, race/ethnicity, diabetes mellitus, and others). Longitudinal studies adopted Cox regression analysis to assess the independent predictors of the incidence of chronic kidney disease; multiple logistic regression analyses were done in cross-sectional surveys. An additional end point was the adjusted estimate of the risk (and 95% CIs) of prevalence of proteinuria in the adult general population according to HBV serological status. Cox proportional hazard regression analysis was carried out to assess the effect of HBV sero-positivity per se on the incidence of chronic kidney disease after adjustment for differential follow-up time and distribution of potential confounders.

Data synthesis and analysis

We weighted the study-specific log odds ratios for case control and cross-sectional studies, and log hazard ratios for longitudinal studies by the inverse of their variance to obtain a pooled effect estimate and its 95% confidence intervals. For each study, we used the estimate of the effect

measure that was adjusted for the largest number of confounders. We present both fixed-effects and random-effects pooled estimates but use and report the latter when heterogeneity was present. We used the random-effects approach, as described by DerSimonian and Laird.¹⁴ Cochrane Q-test was used for quantifying the heterogeneity.¹⁵ The I^2 statistic, which is the percentage of total variation across studies due to heterogeneity rather than chance, was also calculated.¹⁶ The null hypothesis of this test is the absence of heterogeneity. We explored the origin of heterogeneity by restricting the analysis to subgroups of studies defined by study characteristics such as country of origin, CKD stage, and others. Heterogeneity was also evaluated by meta-regression in order to look at the effect of potential and continuous covariates on the outcome of interest. Subgroup or stratified analyses and meta-regression were pre-specified. We performed random-effects meta-regression using the method of moments or maximum likelihood approaches where appropriate, a single predictor is allowed in each model (simple meta-regression). Publication bias was assessed by the Egger test for funnel-plot asymmetry. All analyses were done with the statistical package Comprehensive Meta-Analysis (CMA), version 2.0 (Biostat Inc., USA, 2005). The 5% significance level was adopted for a risk. Every estimate was given with its 95% CIs.

RESULTS

Literature review

As shown in figure 1, we retrieved 424 articles and 98 full-text papers were assessed for eligibility. The list of the papers is reported in the supplementary file 3. Sixteen studies met our inclusion criteria, they were published in 11 papers¹⁹⁻³⁰ (Figure 1) and carried out in 3 countries. Two longitudinal papers addressed various outcomes (the risk of chronic kidney disease and end-stage renal disease) in the same population.²⁰⁻²¹ Four papers^{23-25,28} gave information on the prevalence of chronic kidney disease and proteinuria in the same population. Thus, some studies contributed data on more than one kidney disease outcome, but each cohort was represented once in any meta-analysis. There was a 100% concordance between reviewers with respect to final inclusion and exclusion of studies reviewed based on the predefined inclusion and exclusion criteria. Diagnosis of HBV infection was made by detecting the presence of HBV surface antigen (HBsAg) in serum; in a few reports^{20,21} diagnosis of HBV infection was done by ICD-9 codes. One report addressed the rate of HBV infection by assessing HBcAb serologic status,²² another survey identified HBV infection by patient medical history.²⁹




Figure 1. Flow diagram of study selection.

Patient and study characteristics

Tables 1-3 reports some salient demographic, and clinical characteristics of subjects enrolled in the included studies. The mean age of patient cohorts ranged from 18.9 ± 0.5 to 60.8 ± 11.5 years. The gender distribution ranged from 31.2% to 67.6% male. Five reports were Taiwan, four from China, one from Japan and Hong Kong, respectively. The average follow-up ranged between 3.5 and 6.5

years, among longitudinal studies. The quality scores ranged between 7 and 8 points (cohort/case-control studies), and between 8 and 9 (cross-sectional studies) (Supplementary file 2).

- **Summary estimate of outcome: Incidence of CKD (reduced eGFR or end-stage renal disease).** Four longitudinal studies ($n = 184,937$ patients; 36,192 HBV positive and 148,745 HBV negative patients) gave information on the incidence of CKD (or ESRD) among HBV positive patients¹⁹⁻²² (Table 1). The relationship between positive HBV serologic status and increased incidence of CKD neared the statistical significance, adjusted HR with HBV across the surveys, 2.22 (95% CI, 0.95; 3.50, NS). There was some heterogeneity ($I^2 = 64.7\%$, $P = 0.04$) across the four studies (Figure 2). Publication bias was not found (Egger test, $P = 0.61$) (Figure 3). The subset of longitudinal studies addressing ESRD gave a pooled aHR 3.87 (95%CI, 1.48; 6.25, $P < 0.0001$) among HBV-infected patients and no heterogeneity was recorded (Table 4).
- **Summary estimate of outcome: Prevalence of CKD (reduced eGFR).** Seven studies ($n = 109,889$ unique patients; 8,023 HBV positive and 101,866 HBV-negative patients) with cross-sectional (or case-control) design addressed the prevalence of CKD (or reduced GFR) in HBV-infected patients.²³⁻²⁹ Table 2 shows some demographic, and clinical parameters of subjects enrolled in the included studies. We found no relationship between positive HBV serologic status and increased prevalence of CKD, adjusted OR with HBV across the studies, 1.069 (95% CI, 0.89; 1.248, $P = \text{NS}$). Tests for homogeneity of the aOR across the

Table 1. Longitudinal studies included in the meta-analysis (outcome: frequency of end-stage renal disease or chronic kidney disease).

	Cheng A, <i>et al.</i> *	Chen Y, <i>et al.</i> **	Chen Y, <i>et al.</i> ***	Kong X, <i>et al.</i> ****
Reference year	2006	2014	2015	2016
Country	Hong Kong	Taiwan	Taiwan	China
Study type	Cohort prospective	Nationwide cohort	Nationwide cohort	Cohort prospective
Patients, n	2,838	88,790	88,980	4,329
Mean observation time, yrs	3.5	6.5	6.5	5
HBV rate, n	286 (10.1%)	17,758 (20%)	17,796 (20%)	352 (8.1%)
Anti-HCV rate, n	NA	0	NA	0
Age, yrs	59.7 ± 12.9	NA	NA	46.2 ± 13.7
Male, n	1,169 (41%)	51,990 (58.5%)	52,140 (58.5%)	2,907 (67.2%)
Caucasian, n	0	0	NA	0
Diabetes mellitus, n	2,838 (100%)	7,062 (7.9%)	6,841 (7.7%)	352 (8.1%)
Outcome	ESRD	ESRD	CKD	CKD
Adjusted Effect Estimate, 95% CI	HR	HR	HR	HR
Estimate	4.53 (1.1; 18.5)	3.85 (2.36; 6.27)	2.58 (1.95; 3.42)	1.12 (0.65; 1.95)

* ESRD: need for dialysis, doubling of serum creatinine, or serum creatinine $\geq 500 \mu\text{mol/L}$. ** ESRD: end-stage renal disease requiring long-term dialysis. *** CKD = decreased eGFR ($< 60 \text{ mL/min/1.73 m}^2$) or proteinuria (urine protein $> 1+$). **** CKD: chronic kidney disease stage 1-5.

Table 2. Cross-sectional studies included in the meta-analysis (outcome: frequency of chronic kidney disease, or low estimated glomerular filtration rate).

Reference year	Ishizaka N, et al.	Lee J, et al.	Cai J, et al.	Lin M, et al.	Senghore T, et al.	Zeng Q, et al.	Su S, et al.
Country	2008 Japan	2010 Taiwan	2012 China	2013 China	2013 China	2014 China	2015 Taiwan
Study type	Cross-sectional	Cross-sectional	Cross-sectional	Cross-sectional	Cross-sectional	Cross-sectional	Case-control
Patients, n	12,535	54,966	6,854	3,552	7,745	15,549	8,688
HBV rate, n	130 (1.0%)	5,424 (9.9%)	328 (4.7%)	415 (12.4%)	570	785 (5.0%)	371 (4.2%)
Anti-HCV rate, n	72 (0.6%)	5,189 (9.4%)	NA	188 (5.6%)	NA	94 (0.6%)	169 (1.9%)
Age, yrs	53.1 ± 10.6	60.8 ± 11.5	50.7 ± 10.5	47.5 ± 17	18.9 ± 0.5	49.2 ± 9.3	59.8 ± 15
Male, n	8,054 (64.2%)	17,168 (31.2%)	3,425 (50%)	1,629 (48.6%)	3,265 (42.1%)	10,509 (67.6%)	3,893 (81%)
Caucasian, n	0	0	0	0	0	0	0
Diabetes mellitus, n	2,838 (100%)	5,302 (9.6%)	613 (8.9%)	191 (5.7%)	NA	1,508 (9.7%)	3,182 (36.6%)
Outcome	Low eGFR	Low eGFR	Low eGFR	CKD	CKD	Low eGFR	CKD
Adjusted Effect Estimate, 95% CI	OR	OR	OR	OR	OR	OR	OR
Estimate	0.51 (0.28; 0.92)	1.07 (0.95; 1.15)	1.04 (0.37; 2.93)	1.35 (1.03; 1.77)	1.11 (0.86; 1.43)	0.86 (0.26; 2.89)	1.25 (1.03; 1.52)

Low eGFR: eGFR < 60 mL/min per 1.73 m². CKD: CKD stage 1-5 alternatively eGFR < 60 mL/min per 1.73 m² with or without proteinuria.

Table 3. Studies included in the meta-analysis (outcome: frequency of proteinuria).

Reference year	Huang J, et al.	Ishizaka N, et al.	Lee J, et al.	Cai J, et al.	Zeng Q, et al.
Country	2006 Taiwan	2008 Japan	2010 Taiwan	2012 China	2014 China
Study type	Cross-sectional	Cross-sectional	Cross-sectional	Cross-sectional	Cross-sectional
Patients, n	9,934	12,535	54,966	6,854	15,549
Observation time, yrs	0	0	0	0	0
HBV rate, n	1,363 (13.7%)	130 (1%)	5,424 (9.9%)	328 (4.7%)	785 (5.1%)
Anti-HCV rate, n	646 (6.5%)	72 (0.6%)	5,189 (9.4%)	NA	94 (0.6%)
Age, yrs	55.2 ± 6	53.1 ± 10.6	60.8 ± 11.5	50.7 ± 10.5	49.2 ± 9.3
Male, n	4,291 (43.1%)	8,054 (64.2%)	17,168 (31.2%)	3,425 (50%)	10,509 (67.6%)
Caucasian, n	NA	0	0	0	0
Diabetes mellitus, n	1,241 (12.5%)	NA	5,302 (9.6%)	613 (8.9%)	1,508 (9.7%)
Outcome	Proteinuria	Proteinuria	Proteinuria	Proteinuria	Proteinuria
Adjusted Effect Estimate, 95% CI	OR	OR	OR	OR	OR
Estimate	0.94 (0.75; 1.17)	0.50 (0.23; 1.05)	1.04 (0.91; 1.20)	0.79 (0.53; 1.19)	1.27 (0.85; 1.89)




Figure 2. Impact of HBV positive serologic status on the incidence of CKD (longitudinal studies).




Figure 3. Funnel plot of precision: Impact of HBV seropositive status on the risk of chronic kidney disease (longitudinal studies).

seven studies gave a Q-value (by χ^2 test) of 11.3 ($P = 0.007$) ($I^2 = 47.13$), that is, the homogeneity assumption was rejected (Table 4). No publication bias was found, according to the Egger test ($P = 0.89$).

- **Summary estimate of outcome: prevalence of proteinuria.** Five studies ($n = 99,838$ unique patients, 8,030 being HBV seropositive and 91,808 HBV negative)^{23-25,28,30} evaluated the prevalence of proteinuria according to HBV positive serologic status. Two studies defined proteinuria by semiquantitative urine protein dipstick test^{24,30} and three measured albuminuria by spot urine albumin/creatinine ratio.^{23,25,28} The summary estimate for adjusted OR of proteinuria with HBV was 0.93 (95% CI, 0.76;1.10, $P = \text{NS}$) across the identified studies (Table 4). The homogeneity assumption was not rejected ($Q = 6.02$, $P = 0.19$). Publication bias did not occur (Egger test, $P = 0.42$).

- **Stratified analysis and meta-regression.** As shown in table 4, there was substantial difference in pooled effect estimates across designs (i.e., cross-sectional *vs.* longitudinal studies) and the homogeneity assumption was rejected in many subsets. As listed in table 5, meta-regression demonstrated an inverse relationship between the frequency of males ($P = 0.006$) and the outcome of interest (adjusted HR of incidence of CKD among HBV positive patients). In addition, a direct relationship between follow-up duration ($P = 0.007$) and the outcome of interest (adjusted HR of incidence of CKD among HBV positive patients) was noted.

There was no significant difference in outcomes according to the diagnosis of HBV infection (data not shown).

DISCUSSION

The association between HBV infection and chronic kidney disease in the general population is controversial even if the renal involvement of hepatitis B virus infection was first reported four decades ago.³¹ The relationship between hepatitis B virus infection and CKD occurs in several ways- some forms of renal disease are induced by HBV infection and patients with chronic kidney disease are at increased risk for acquiring HBV. In the current review, we have summarized the scientific evidence and carried out a meta-analysis on the exposure to HBV infection and the risk of chronic kidney disease and proteinuria in the adult general population. This meta-analysis (16 studies, $n = 394,664$ patients) should suggest an association between positive serologic status for HBV and an increased risk of chronic kidney disease, aHR being 2.22 (95% Confidence Interval, 0.95; 3.50) in HBV infected individuals

Table 4. Summary measure for adjusted effect estimate according to HBV serologic status among various subgroups of interest.

	N	Adjusted Effect Estimate (Random-Effects Model)	Q Value (by χ^2 test)	P
Outcome: chronic kidney disease (incidence), aHR				
Longitudinal studies (All)	4	2.22 (0.95; 3.50)	8.57	64.7
Longitudinal studies (outcome: CKD)	2	1.85 (0.41; 3.27)	5.87	82.9
Longitudinal studies (outcome: ESRD)	2	3.87 (1.48; 6.25)	0.00	0.0
Quality score ≥ 8	2	2.71 (1.95; 3.47)	0.83	0.0
Outcome: chronic kidney disease (prevalence), aOR				
All studies	7	1.07 (0.89; 1.24)	11.3	47.1
Studies based on low eGFR (outcome)	5	0.84 (0.41; 1.28)	7.63	60.6
Studies based on CKD (outcome)	3	1.22 (1.03; 1.40)	0.85	0.0
Cross-sectional studies based on CKD (outcome)	2	1.19 (0.93; 1.45)	0.77	0.0
Quality score ≥ 9	3	1.07 (1.0; 1.15)	1.57	0.00
Outcome: proteinuria (prevalence), aOR				
All studies	5	0.93 (0.76; 1.10)	6.02	33.5
Studies from China	2	0.96 (0.51; 1.42)	1.62	38.5
Quality score ≥ 9	2	0.98 (0.78; 1.18)	1.29	22.7
Studies based on spot urine albumin/creatinine ratio	3	0.82 (0.44; 1.21)	3.34	40.1
Studies based on standard dispstick analysis	2	1.00 (0.87; 1.13)	0.48	0.0

Cheng, et al.:¹⁹ HR adjusted for age, age of onset of diabetes mellitus, gender, smoking use, systolic and diastolic blood pressure, body mass index, fasting plasma glucose, total cholesterol, triglyceride, white cell count, estimated glomerular filtration rate, and albumin:creatinine ratio. Chen, et al.:²⁰ HR adjusted for age, gender, diabetes, hypertension, coronary artery disease, hyperlipidaemia, cirrhosis, use of herbs containing aristolochic acid, geographic region, urbanization level, enrollee category, number of medical visits, propensity score, and Charlson comorbidity index score. Chen, et al.:²¹ HR adjusted for gender, age, diabetes mellitus, hypertension, coronary artery disease, hyperlipidaemia, glomerulonephritis, chronic pyelonephritis, nephrolithiasis, renal and urinary tract tumor, cirrhosis, use of herbs containing aristolochic acid, geographic region, urbanization level, enrollee category, number of medical visits in one year before study entry, Charlson comorbidity index score, propensity score, and interactions terms. Kong, et al.:²² HR adjusted for age, gender, hypertension, diabetes, body mass index, uric acid, total cholesterol, triglycerides, LDL cholesterol, HDL cholesterol. Ishizaka, et al.:²³ OR adjusted for age, gender, fasting plasma glucose, systolic blood pressure, and anti-HCV seropositive status. Lee, et al.:²⁴ OR adjusted for age, gender, educational status, body mass index, haemoglobin level, albumin level, cholesterol level, uric acid level, hypertension, and diabetes mellitus. Cai, et al.:²⁵ OR adjusted for age, gender, hypertension, diabetes, waist circumference, HDL cholesterol levels, total cholesterol levels, and nephrolithiasis. Lin, et al.:²⁶ OR adjusted for age, gender, annual income, hypertension, diabetes mellitus, cardiovascular disease, stroke, gout, liver disease, urinary tract disease, cancer, Chinese herbs use, oral analgesic use, analgesic injection, health supplements, cigarette smoking, betel-nut chewing, alcohol drinking, metabolic syndrome, hyperuricemia, haemoglobin, and positivity for anti-HCV. Senghore, et al.:²⁷ OR adjusted for age, gender, body mass index, blood pressure, urine occult blood, blood urea nitrogen, uric acid, total cholesterol. Zeng, et al.:²⁸ OR adjusted for age, gender, anti-HCV seropositive status, arterial hypertension, diabetes mellitus, body mass index, albumin, HDL cholesterol levels, LDL cholesterol levels, triglycerides, total cholesterol, and uric acid. Su, et al.:²⁹ OR adjusted for gender, age, obesity, income, HCV, hyperuricaemia, anaemia, hyperlipidaemia, smoking status, alcohol abuse, betel nut, exercise habits, groundwater using. Huang, et al.:³⁰ OR adjusted for diabetes, hypertension, HCV serologic status, age, triglycerides, body mass index, ALT level, total cholesterol.

Table 5. Meta-regression: impact of continuous covariates on the outcome of interest (incidence of CKD).

	Point estimate (std error)	95% CI	P-value
Diabetes	1.35 (7.88)	-14.1; 16.8	0.86
Year	-1.07 (0.41)	-1.88;-0.27	0.008
Follow-up, time	1.03 (0.38)	0.27; 1.79	0.007
Males	-17.5 (6.39)	-30.0; -5.00	0.006
Size	0.0003 (0.0001)	0.000; 0.000	0.007

compared with HBV negative. The subset of longitudinal studies addressing ESRD gave a pooled aHR 3.87 (95%CI, 1.48; 6.25, $P < 0.0001$) among HBV-infected patients, without heterogeneity.

Several pieces of evidence are in keeping with a detrimental role of HBV on the development of chronic kid-

ney disease.³²⁻³⁹ In the 2-year cross-sectional HARPE study,³² renal abnormalities were highly prevalent in chronic HBV infection and occurred before the initiation of any antiviral therapy towards HBV. Around 64% of the patients enrolled in the HARPE study ($n = 260$) were found to have kidney disease according to the KDOQI/KDIGO classification. In their observational and longitudinal study, Mallet, *et al.*³³ observed 214 patients with chronic HBV infection who were treated with various nucleos(t)ide analogues, the eGFR remained stable or increased over time in patients with chronic HBV mono-infection with a baseline eGFR of 90 mL/min/1.73 m² or higher and treated with tenofovir disoproxil fumarate or entecavir. In the GLOBE study,³⁴ a significant improvement in mean GFR was noted in patients treated with telbivudine for 2 years, but not in those on lamivudine. GLOBE extension studies

demonstrated that the improvement was maintained throughout 4-6 years of continuous telbivudine therapy. The mean increase in eGFR was ± 14.9 mL/min/1.73 m² at week 208 ($P < 0.0001$). In 74% (165 of 223) of the telbivudine-treated patients with baseline eGFR of 60-89 mL/min/1.73 m² (CKD stage 2), renal function improved to ≥ 90 mL/min/1.73 m² after 4 years of treatment. A prospective survey from Germany reported recently that GFR (calculated with the CKD-EPI equation), declined by approximately -2 mL/min/year in HBsAg-positive ($n = 60$) untreated patients over a median follow-up of 24 months.³⁵

Chronic kidney disease is an important public-health problem which significantly increases the likelihood of adverse outcomes and high health-care costs; in addition to the conventional risk factors for chronic kidney disease in the general population, HBV may be an additional agent. Various mechanisms have been implicated in the adverse impact of HBV sero-positive status on chronic kidney disease, including an accelerated endothelial dysfunction at renal level. An atherogenic activity of HBV has been suggested to explain a five-fold increased risk of cardiovascular events in a selected cohort of HBsAg positive patients with type 2 diabetes and overt nephropathy over a median follow-up of 24 months.¹⁷ Steatosis is a typical feature of chronic HBV infection and could induce lipid peroxidation and increase plasma inflammatory biomarkers.³⁹ The pathogenesis of HBV-associated nephropathy is still under investigation; however, the small number of patients who develop glomerulonephritis suggests that concomitant factors are needed for development of nephropathy (i.e., genetic susceptibility, abnormalities in cell-mediated immunity, and/or environmental conditions).⁵ These pieces of evidence are in apparent conflict with other findings from the general population- chronic HCV is an important factor for developing insulin resistance, type 2 diabetes mellitus and atherosclerosis.⁴¹ Such relationships in patients with chronic hepatitis B are not so straightforward.^{40, 42-43}

The findings from our meta-analysis are subject to several limitations. First, many studies were cross-sectional, a design that does not allow for causal inference and can overestimate relative risks given its reliance on prevalence ratios. When restricted to cross-sectional studies, no significant relationship was found between hepatitis B serologic status and frequency of CKD and proteinuria. Therefore, there is some evidence that the findings may be impacted by study design. Second, we included in the current review only studies providing adjusted estimates of outcomes (risk of end-stage renal disease or chronic kidney disease, or proteinuria), but residual confounding (confounding remaining after adjustment) likely exists as full information has not been given on various covariates in all studies retrieved. As

an example, information on HBV DNA or HBV genotypes, socioeconomic status, compliance with medical visits over follow-up, and substance abuse which are important potential confounders was incomplete. Finally, the occurrence of significant heterogeneity clearly precluded more definitive conclusions; our subgroup analysis with meta-regression was not able to capture all the sources of heterogeneity observed. As an example, all the studies enrolled in our systematic review came from Asia and we need studies from other continents.

In conclusion, this meta-analysis of observational studies should suggest a relationship between HBV infection and higher incidence of low eGFR and/or end-stage renal disease in the adult general population. We need additional studies with appropriate size and design (i.e., prospective longitudinal studies) to increase our knowledge on this issue and to explore potential mechanisms underlying such association. A heightened awareness of an increased chronic kidney disease risk should dictate more careful follow-up of renal defects among patients with hepatitis B virus infection.

SUPPORTING INFORMATION

- **Supplementary file 1.** PRISMA 2009 check list. PRISMA's items and their application within the paper.
- **Supplementary file 2.** Quality study. Details on the quality study process (cohort and cross-sectional studies).
- **Supplementary file 3.** Excluded papers. List of excluded papers sorted by publication year.

ABBREVIATIONS

- **ACR:** albumin to creatinine ratio.
- **APR:** albumin to protein ratio.
- **CC:** case-control.
- **CKD:** chronic kidney disease.
- **CI:** confidence intervals.
- **Co:** cohort.
- **CS:** cross-sectional.
- **eGFR:** estimated glomerular filtration rate.
- **ESRD:** end-stage renal disease.
- **HBV:** hepatitis B virus.
- **HBcAb:** hepatitis B core antibody.
- **HBsAg:** hepatitis B surface antigen.
- **HCV:** hepatitis C virus.
- **HR:** hazard ratio.
- **MDRD:** Modification of Diet in Renal Disease.
- **NOS:** Newcastle/Ottawa Scale.
- **OR:** odds ratio

ACKNOWLEDGMENTS

This work was supported in part by a 'Project Glomerulonephritis' grant, in memory of Pippo Neglia, by Associazione Amici del Croff-Onlus. The funders had no role in study design, data collection analysis, decision to publish, or preparation of the manuscript

DISCLOSURES

None.

REFERENCES

1. Eggers P. Has the incidence of end-stage renal disease in the USA and other countries stabilized? *Curr Opin Nephrol Hypertens* 2011; 20: 241-5.
2. Chacko E, Surrin S, Mubarak Sani T, Pappachan J. Chronic viral hepatitis and chronic kidney disease. *Postgrad Med J* 2010; 86: 486-92.
3. Fabrizi F, Verdesca S, Messa P, Martin P. Hepatitis C virus infection increases the risk of developing chronic kidney disease: a systematic review and meta-analysis. *Dig Dis Sci* 2015; 60: 3801-13.
4. Fabrizi F, Dixit V, Martin P, Messa P. Hepatitis C virus increases the risk of kidney disease among HIV-positive patients: systematic review and meta-analysis. *J Med Virol* 2016; 88: 487-97.
5. Johnson R, Couser W. Hepatitis B infection and renal disease: clinical, immunopathogenetic and therapeutic considerations. *Kidney Int* 1990; 37: 663-76.
6. Zeng C, Chen H, Wang R, Chen Y, Zhang S, Liu L, Li L, et al. Aetiology and clinical characteristics of membranous nephropathy in Chinese patients. *Am J Kidney Dis* 2008; 52: 691-8.
7. Deng C, Song W, Liang H, Feng C, Sheng Y, Wang M. Chronic hepatitis B serum promotes apoptotic damage in human renal tubular cells. *World J Gastroenterol* 2006; 12: 1752-6.
8. Pais R, Rusu E, Zilisteanu D, Circiumaru A, Micu L, Voiculescu M, Poynard T, et al. Prevalence of steatosis and insulin resistance in patients with chronic hepatitis B compared with chronic hepatitis C and non-alcoholic fatty liver disease. *Eur J Intern Med* 2015; 26: 30-6.
9. Pawlak K, Pawlak D, Mysliwiec M. Hepatitis intensified oxidative stress, MIP-1 beta and RANTES plasma levels in uraemic patients. *Cytokine* 2004; 28: 197-204.
10. Liberati A, Altman D, Tetzlaff J, Mulrow C, Gotzsche P, Ioannidis J, Clarke M, (PRISMA Group). The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. *J Clin Epidemiol* 2009; 62: e1-e34.
11. Poynard T, Conn H. The retrieval of randomised clinical trials in liver diseases from the medical literature: a comparison of Medlars and manual methods. *Control Clin Trials* 1985; 6: 271-9.
12. Institute OHR. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Disponible en: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp (access date 26 Apr 2014).
13. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. *Am J Kidney Dis* 2002; 39(Suppl. 1): S1-S266.
14. DerSimonian R, Laird N. Meta-analysis in clinical trials. *Control Clin Trials* 1986; 7: 177-88.
15. Petitti D. Approaches to heterogeneity in meta-analysis. *Stat Med* 2001; 20: 3625-33.
16. Higgins J, Thompson S, Deeks J, Altman D. Measuring inconsistencies in meta-analysis. *Br Med J* 2003; 327: 557-60.
17. Lo M, Lee K, Chan N, Leung W, Ko G, Chan W, So W, et al. Effects of gender, *Helicobacter pylori* and hepatitis B virus serology status on cardiovascular and renal complications in Chinese type 2 diabetics with overt nephropathy. *Diabetes Obesity Metabolism* 2004; 6: 223-30.
18. Lee J, Lin M, Chang J, Hung C, Chang J, Chen H, Yu M, et al. Hepatitis C virus infection increases risk of developing end-stage renal disease using competing risk analysis. *Plos One* 2014; 9: e100790.
19. Cheng A, Kong P, Wong V, So W, Chan H, Ho C, Lam C, et al. Chronic hepatitis B viral infection independently predicts renal outcome in type 2 diabetic patients. *Diabetologia* 2006; 49: 1777-84.
20. Chen Y, Su Y, Li C, Wu C, Lee M. A nationwide cohort study suggests chronic hepatitis B virus infection increases the risk of end-stage renal disease among patients in Taiwan. *Kidney Int* 2015; 87: 1030-8.
21. Chen Y, Su Y, Li C, Hung S. 13-year nationwide cohort study of chronic kidney disease risk among treatment-naive patients with chronic hepatitis B in Taiwan. *BMC Nephrol* 2015; 16: 110.
22. Kong X, Ma X, Su H, Xu D. Relationship between occult hepatitis B virus infection and chronic kidney disease in a Chinese population-based cohort. *Chronic Dis Transl Med* 2016; 2: 55-60.
23. Ishizaka N, Ishizaka Y, Seki G, Nagai R, Yamakado M, Koike K. Association between hepatitis B/C viral infection, chronic kidney disease and insulin resistance in individuals undergoing general health screening. *Hepatol Res* 2008; 38: 775-83.
24. Lee J, Lin M, Yang Y, Lu S, Chen H, Hwang S. Association of hepatitis C and B virus infection with CKD in an endemic area in Taiwan: a cross-sectional study. *Am J Kidney Dis* 2010; 56: 23-31.
25. Cai J, Fan X, Mou L, Gao B, Liu X, Li J, Liu L, et al. Association of reduced renal function with hepatitis B virus infection and elevated alanine aminotransferase. *Clin J Am Soc Nephrol* 2012; 7: 1561-6.
26. Lin M, Chiu Y, Lee C, Yu H, Chen H, Wu M, Hwang S. Factors associated with CKD in the elderly and non-elderly population. *Clin J Am Soc Nephrol* 2013; 8: 33-40.
27. Senghore T, Su F, Lin Y, Chu F, Yeh C. Association between hepatitis B virus infection and chronic kidney disease in university students receiving physical check-ups: a cross-sectional study. *J Exp Clin Med* 2013; 5: 181-6.
28. Zeng Q, Gong Y, Dong S, Xiang H, Wu Q. Association between exposure to hepatitis B virus and chronic kidney disease in China. *J Int Med Res* 2014; 42: 1178-84.
29. Su S, Lin C, Kao S, Wu C, Lu K, Lai C, Yang H, et al. Risk factors and their interaction on chronic kidney disease: a multicentre case control study in Taiwan. *BMC Nephrol* 2015; 16: 83.
30. Huang J, Chuang W, Dai C, Ho C, Hwang S, Chen S, Lin Z, et al. Viral hepatitis and proteinuria in an area endemic for hepatitis B and C infections: another chain of link? *J Int Med* 2006; 260: 255-62.
31. Combes B, Shorey J, Barrera A, Stastny P, Eigenbrodt E, Hull A, Carter N. Glomerulonephritis with deposition of Australia antigen-antibody complexes in glomerular basement membrane. *Lancet* 1971; 2: 234-7.
32. Amet S, Bronowicki J, Thabut D, Zoulim F, Bourliere M, Math-

- urin P, de Ledinghen V, et al. Prevalence of renal abnormalities in chronic HBV infection: the HARPE study. *Liver Int* 2015; 148-55.
33. Mallet V, Schwarzsinger M, Vallet-Pichard A, Fontaine H, Corouge M, Sogni P, Pol S. Effect of nucleoside and nucleotide analogues on renal function in patients with chronic hepatitis B virus mono-infection. *Clin Gastroenterol Hepatol* 2015; 13: 1181-8.e1.
 34. Gane E, Deray G, Liaw Y, Lim S, Lai C, Rasenack J, Wang Y, et al. Telbivudine improves renal function in patients with chronic hepatitis B. *Gastroenterology* 2014; 146: 138-46.
 35. Tsai M, Chen C, Tseng P, Hung C, Chiu K, Chang K, Yen Y, et al. Does nucleos(t)ide analogues treatment affect renal function in chronic hepatitis B patients who have already decreased eGFR? A longitudinal study. *PLoS One* 2016; 11: e0149761.
 36. Mauss S, Berger F, Filmann N, Hueppe D, Henke J, Hegener P, Athmann C, et al. Effect of HBV polymerase inhibitors on renal function in patients with chronic hepatitis B. *J Hepatol* 2011; 55: 1235-40.
 37. Shin J, Kwon H, Jang H, Lee J, Gwak G, Huh W, Jung S, et al. Risk factors for renal functional decline in chronic hepatitis B patients receiving oral antiviral agents. *Medicine* 2016; 95: e2400.
 38. Wong G, Tse Y, Wong W, Yip T, Tsoi K, Chan H. Long-term safety of oral nucleos(t)ide analogues for patients with chronic hepatitis B: A cohort study of 53,500 subjects. *Hepatology* 2015; 62: 689-93.
 39. Turan I, Yapali S, Bademkiran F, Kose T, Duman S, Sozbilen M, Gunsar F, et al. Telbivudine in liver transplant recipients: renal protection does not overcome the risk of polyneuropathy and myopathy. *Liver Int* 2015; 21: 1066-75.
 40. Shimizu I, Kohno N, Tamaki K, Shono M, Huang H, He J, Yao D. Female hepatology: favourable role of estrogen in chronic liver disease with hepatitis B virus infection. *World J Gastroenterol* 2007; 13: 4295-305.
 41. Adinolfi L, Zampino R, Restivo L, Lonardo A, Guerrera B, Marrone A, Nascimbeni F, et al. Chronic hepatitis C virus infection and atherosclerosis: clinical impact and mechanisms. *World J Gastroenterol* 2014; 20: 3410-7.
 42. Wang C, Chen C, Lee M, Yang H, Hsiao C. Chronic hepatitis B infection and risk of atherosclerosis-related mortality: a 17-year follow-up study based on 22,472 residents in Taiwan. *Atherosclerosis* 2010; 211: 624-9.
 43. Jacurska P, Drazilova S, Fedacko J, Pella D, Janicko M. Association between hepatitis B and metabolic syndrome: current state of art. *World J Gastroenterol* 2016; 22: 155-64.

Correspondence and reprint request:

Fabrizio Fabrizi, M.D.

Division of Nephrology, Maggiore Hospital and
IRCCS Foundation, Pad. Croff, Via Commenda 15, 20122,
Milan, Italy.

Tel.: (39) 2 5503-4553. Fax: (39) 2 5503-3770

E-mail: fabrizi@policlinico.mi.it

SUPPLEMENTARY FILE 1.
PRISMA 2009 check list.
PRISMA's items and their application within the paper.

Section/topic	No.	Checklist item	Reported on page No.
TITLE			
Title	1	Identify the report as a systematic review, meta-analysis, or both.	1
ABSTRACT			
Structured summary	2	Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.	1
INTRODUCTION			
Rationale	3	Describe the rationale for the review in the context of what is already known.	1-2
Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).	1-2
METHODS			
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.	Not available
Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.	2
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	2
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	2
Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	2
Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	2
Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	2
Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	2
Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).	3

Synthesis of results	14	Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I^2) for each meta-analysis.	3
Risk of bias across studies	15	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).	3-4
Additional analyses	16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.	3-4
RESULTS			
Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.	3-6
Study characteristics	18	For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.	3-6
Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).	3-6
Results of individual studies	20	For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.	3-6
Synthesis of results	21	Present results of each meta-analysis done, including confidence intervals and measures of consistency.	3-6
Risk of bias across studies	22	Present results of any assessment of risk of bias across studies (see Item 15).	3-6
Additional analysis	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).	3-6
DISCUSSION			
Summary of evidence	24	Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).	6-8
Limitations	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).	6-8
Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implications for future research.	6-8
FUNDING			
Funding	27	Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.	9

From: Moher D, Liberati A, Tetzlaff J, Altman DG. The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. *PLoS Med* 6(6): e1000097. doi:10.1371/journal.pmed1000097. For more information, visit: www.prisma-statement.org

SUPPLEMENTARY FILE 2.

Quality study.

Details on the quality study process (cohort and cross-sectional studies).

NEWCASTLE - OTTAWA QUALITY ASSESSMENT SCALE

(Cohort studies)

Note: A study can be awarded a maximum of one star for each numbered item within the Selection and Outcome categories. A maximum of two stars can be given for Comparability (maximum 8 items, 9 stars).

Selection (Maximum 4 stars).

1. Representativeness of the exposed cohort.
 - a) Truly representative of the average _____ (describe) in the community.
 - b) Somewhat representative of the average _____ in the community.
 - c) Selected group of users, e.g. nurses, volunteers.
 - d) No description of the derivation of the cohort.
2. Selection of the non-exposed cohort.
 - a) Drawn from the same community as the exposed cohort.
 - b) Drawn from a different source.
 - c) No description of the derivation of the non exposed cohort.
3. Ascertainment of exposure.
 - a) Secure record (e.g. surgical records).
 - b) Structured interview.
 - c) Written self-report.
 - d) No description.
4. Demonstration that outcome of interest was not present at start of study.
 - a) Yes.
 - b) No.

Comparability (Maximum 2 stars).

1. Comparability of cohorts on the basis of the design or analysis.
 - a) Study controls for _____ (select the most important factor).
 - b) Study controls for any additional factor (this criteria could be modified to indicate specific control for a second important factor).

Outcome (Maximum 3 stars).

1. Assessment of outcome.
 - a) Independent blind assessment.
 - b) Record linkage.
 - c) Self report.
 - d) No description.

2. Was follow-up long enough for outcomes to occur.
 - a) Yes (select an adequate follow up period for outcome of interest).
 - b) No.
3. Adequacy of follow up of cohorts.
 - a) Complete follow up - all subjects accounted for.
 - b) Subjects lost to follow up unlikely to introduce bias - small number lost - > ____ % (select an adequate %) follow up, or description provided of those lost).
 - c) Follow up rate < ____% (select an adequate %) and no description of those lost.
 - d) No statement.

NEWCASTLE-OTTAWA QUALITY ASSESSMENT SCALE

(Cohort studies)

Cheng A, et al. (*Diabetologia*, 2006).

- SELECTION.
 - 1c no star.
 - 2a one star.
 - 3a one star.
 - 4a one star.
- COMPARABILITY.
 - 1a one star.
 - 1b one star.
- OUTCOME.
 - 1b one star.
 - 2a one star.
 - 3d no star.

N = 7 stars

Chen Y, et al. (*Kidney Int*, 2015).

Chen Y, et al. (*BMC Nephrology*, 2015).

- SELECTION.
 - 1a one star.
 - 2a one star.
 - 3a one star.
 - 4a one star.

- COMPARABILITY.
 - 1a one star.
 - 1b one star.

- OUTCOME.
 - 1b one star.
 - 2a one star.
 - 3d no star.

N = 8 stars

Kong X, et al. (*Chronic Dis Transl Med*, 2016).

- SELECTION.
 - 1b one star.
 - 2a one star.
 - 3d one star.
 - 4a one star.

- COMPARABILITY.
 - 1a one star.

- OUTCOME.
 - 1b one star.
 - 2a one star.
 - 3d no star.

N = 7 stars

NEWCASTLE - OTTAWA QUALITY ASSESSMENT SCALE

(Adapted for cross-sectional studies) (Maximum 7 items, 10 stars).

Selection (Maximum 5 stars).

1. Representativeness of the sample:
 - a) Truly representative of the average in the target population* (all subjects or random sampling).
 - b) Somewhat representative of the average in the target population* (non-random sampling).
 - c) Selected group of users.
 - d) No description of the sampling strategy.
2. Sample size:
 - a) Justified and satisfactory.*
 - b) Not justified.
3. Non-respondents:
 - a) Comparability between respondents and non-respondents characteristics is established, and the response rate is satisfactory.*
 - b) The response rate is unsatisfactory, or the comparability between respondents and non-respondents is unsatisfactory.
 - c) No description of the response rate or the characteristics of the responders and the non-responders.
4. Ascertainment of the exposure (risk factor):
 - a) Validated measurement tool.**
 - b) Non-validated measurement tool, but the tool is available or described.*
 - c) No description of the measurement tool.

Comparability (Maximum 2 stars).

1. The subjects in different outcome groups are comparable, based on the study design or analysis. Confounding factors are controlled.
 - a) The study controls for the most important factor (select one). *
 - b) The study control for any additional factor. *

Outcome: (Maximum 3 stars)

1. Assessment of the outcome:
 - a) Independent blind assessment.**
 - b) Record linkage.**
 - c) Self report.*
 - d) No description.
2. Statistical test:
 - a) The statistical test used to analyze the data is clearly described and appropriate, and the measurement of the association is presented, including confidence intervals and the probability level (p value).*
 - b) The statistical test is not appropriate, not described or incomplete.

This scale has been adapted from the Newcastle-Ottawa Quality Assessment Scale for cohort studies to perform a quality assessment of cross-sectional studies for the systematic review.

NEWCASTLE - OTTAWA QUALITY ASSESSMENT SCALE

(Cross-sectional studies)

CAI J, et al. (*Clin J Am Soc Nephrol*, 2012).

- SELECTION.
 - 1a one star.
 - 2a one star.
 - 3 not applicable (no star).
 - 4a two stars.

- COMPARABILITY.
 - 1a one star.
 - 1b one star.

- OUTCOME.
 - 1b two stars.
 - 2a one star.

N = 9 stars

ISHIZAKA N, et al. (*Hepat Res*, 2008).

- SELECTION.
 - 1d no star.
 - 2a one star.
 - 3 not applicable (no star).
 - 4a two stars.

- COMPARABILITY.
 - 1a one star.
 - 1b one star.

- OUTCOME.
 - 1b two stars.
 - 2a one star.

N = 8 stars

ZENG Q, et al. (*J Int Med Res*, 2014).

- SELECTION.
 - 1d no star.
 - 2a one star.
 - 3 not applicable (no star).
 - 4a two stars.

- COMPARABILITY.
 - 1a one star.
 - 1b one star.

- OUTCOME.
 - 1b two stars.
 - 2a one star.

N = 8 stars

Lin M, et al. (*Clin J Am Soc Nephrol*, 2013).

- SELECTION.
 - 1a one star.
 - 2a one star.
 - 3 not applicable (no star).
 - 4a two stars.

- COMPARABILITY.
 - 1a one star.
 - 1b one star.

- OUTCOME.
 - 1b two stars.
 - 1a one star.

N = 9 stars

Lee J, et al. (*Am J Kidney Dis*, 2010).

- SELECTION.
 - 1d no star.
 - 2a one star.
 - 3 one star.
 - 4a two stars.

- COMPARABILITY.
 - 1a one star.
 - 1b one star.

- OUTCOME.
 - 1b two stars.
 - 1a one star.

N = 9 stars

SENGHORE T, et al. (*J Exp Clin Med*, 2013).

- SELECTION.
 - 1c one star.
 - 2a one star.
 - 3a one star.
 - 4a one star.
- COMPARABILITY.
 - 1a one star.
- OUTCOME.
 - 1b one star.
 - 2a one star.

N = 7 stars

HUANG J, et al. (*J Intern Med*, 2006).

- SELECTION.
 - 1b one star.
 - 2a one star.
 - 3a one star.
 - 4c one star.
- COMPARABILITY.
 - 1a one star.
- OUTCOME.
 - 1b one star.
 - 2a one star.

N = 7 stars

NEWCASTLE - OTTAWA QUALITY ASSESSMENT SCALE

(Case-control studies)

Note: A study can be awarded a maximum of one star for each numbered item within the Selection and Exposure categories. A maximum of two stars can be given for Comparability.

Selection.

1. Is the case definition adequate?
 - a) Yes, with independent validation.
 - b) Yes, e.g. record linkage or based on self-reports.
 - c) No description.
2. Representativeness of the cases.
 - a) Consecutive or obviously representative series of cases.
 - b) Potential for selection biases or not stated.
3. Selection of controls.
 - a) Community controls.
 - b) Hospital controls.
 - c) No description.
4. Definition of controls.
 - a) No history of disease (endpoint)
 - b) No description of source

Comparability.

1. Comparability of cases and controls on the basis of the design or analysis.
 - a) Study controls for _____ (select the most important factor).
 - b) Study controls for any additional factor (this criteria could be modified to indicate specific control for a second important factor.)

Exposure.

1. Ascertainment of exposure.
 - a) Secure record (e.g. surgical records).
 - b) Structured interview where blind to case/control status.
 - c) Interview not blinded to case/control status.
 - d) Written self-report or medical record only.
 - e) No description.
2. Same method of ascertainment for cases and controls.
 - a) Yes.
 - b) No.
3. Non-response rate.
 - a) Same rate for both groups.
 - b) Non respondents described.
 - c) Rate different and no designation.

Su S, et al. (*BMC Nephrol*, 2015).

- SELECTION.
 - 1a one star.
 - 2a one star.
 - 3a one star.
 - 4a one star.
- COMPARABILITY.
 - 1a one star.
 - 1b one star.
- OUTCOME.
 - 1a one star.
 - 2a one star.
 - 3c none.

N = 8 stars

SUPPLEMENTARY FILE 3.

Excluded papers.

List of excluded papers sorted by publication year.

STUDIES BASED ON UNADJUSTED ANALYSIS

1. Lo M, Lee K, Chan N, Leung W, Ko G, Chan W, So W, et al. Effects of gender, *Helicobacter pylori* and hepatitis B virus serology status on cardiovascular and renal complications in Chinese type 2 diabetics with overt nephropathy. *Diabetes Obesity Metabolism* 2004; 6: 223-30.

STUDIES BASED ON SIMILAR DATABASE

1. Lee J, Lin M, Chang J, Hung C, Chang J, Chen H, Yu M, et al. Hepatitis C virus infection increases risk of developing end-stage renal disease using competing risk analysis. *Plos One* 2014; 9: e100790.

HBV AND CKD: NARRATIVE REVIEWS (AND META-ANALYSES) (NATIVE KIDNEYS, ADULTS ONLY)

1. Wang W, Wu M, Ma F, Sun T, Xu Z. Meta-analysis of the efficacy and safety of nucleotide/nucleoside analog monotherapy for hepatitis B virus-associated glomerulonephritis. *Clin Nephrol* 2015; Dec 4 [Epub ahead of print].
2. Naicker S, Ranmanian S, Kopp J. HIV and chronic kidney disease. *Clin Nephrol* 2015; 83(Suppl. 1): 32-8.
3. Gluhovschi G, Petrica L, Sporea I, Timar R, Curescu M, Velciov S, Gluhovschi C. Chronic kidney disease-chronic liver disease. An Immunologic cross-talk. *Rom J Intern Med* 2015; 53: 3-12.
4. Liang T, Block T, McMahon B, Ghany M, Urban S, Guo J, Locarnini S, et al. Present and future therapies of hepatitis B: from discovery to cure. *Hepatology* 2015 Aug 3. doi: 10.1002/hep.28025 [Epub ahead of print] Review.
5. Mikolajczyk A, Aronsohn A. Current management of chronic hepatitis B and C in chronic kidney disease. *Adv Chronic Kidney Dis* 2015; 22: 352-60.
6. Cholongitas E, Tziomalos K, Pipili C. Management of patients with hepatitis B in special populations. *World J Gastroenterol* 2015; 21(6): 1738-48. doi: 10.3748/wjg.v21.i6.1738. Review.
7. Gupta A, Quigg R. Glomerular diseases associated with hepatitis B and C. *Adv Chronic Kidney Dis* 2015; 22: 343-51.
8. Pipili C, Cholongitas E, Papatheodoridis G. Review article: nucleos(t)ide analogues in patients with chronic hepatitis B virus infection and chronic kidney disease. *Aliment Pharmacol Ther* 2014; 39: 35-46.
9. Murakami C, Melda Urekli H, Atta MG. Antiviral medications for the treatment of hepatitis B and C infections and their effects on kidney function. *Minerva Gastroenterol Dietol* 2014; 60(3): 177-89. Epub 2014 Jul 16.
10. Yapali S, Lok A. Potential benefit of telbivudine on renal function does not outweigh its high rate of antiviral drug resistance and other adverse effects. *Gastroenterology* 2014; 146: 15-9.
11. Vergani D, Mieli-Vergani D. Autoimmune manifestations in viral hepatitis. *Semin Immunopathol* 2013; 35: 73-85.
12. Pipili C, Papatheodoridis G, Cholongitas E. Treatment of hepatitis B in patients with chronic kidney disease. *Kidney Int* 2013; 84: 880-5.
13. Zheng X, Wei R, Tang L, Li P, Zheng X. Meta-analysis of combined therapy for adult hepatitis B virus-associated glomerulonephritis. *World J Gastroenterol* 2012; 18: 821-32.
14. Urbanek P. Viral hepatitis infections in chronic kidney disease patients and renal transplant recipients. *Kidney Blood Press Res* 2012; 35: 454-67.
15. Hrstic I, Ostojic R. Chronic liver diseases in patients with chronic kidney disease. *Acta Med Croatica* 2011; 65: 349-53.
16. Papafragkakis H, Fabrizi F, Martin P. Viral hepatitis in renal transplantation. *Clin Nephrol* 2011; 76: 29-39.
17. Yi Z, Jie Y, Nan Z. The efficacy of anti-viral therapy on hepatitis B virus-associated glomerulonephritis: a systematic review and meta-analysis. *Ann Hepatol* 2011; 10: 165-73.
18. Kalia H, Fabrizi F, Martin P. Hepatitis B virus and renal transplantation. *Transplant Rev (Orlando)* 2011; 25: 102-9.
19. Elewa U, Sandri A, Kim W, Fervenza F. Treatment of hepatitis B virus-associated nephropathy. *Nephron Clin Pract* 2011; 119: c41-c49.
20. Huskey J, Wiseman A. Chronic viral hepatitis in kidney transplantation. *Nat Rev Nephrol* 2011; 7: 156-65.
21. Terrier B, Cacoub P. Hepatitis B virus, extrahepatic immunologic manifestations and risk of viral reactivation. *Rev Med Interne* 2011; 32(10): 622-7. doi: 10.1016/j.revmed.2010.08.013. Epub 2010 Sep 25. Review. French.
22. Roccatello D, Solfietti L, Salussolia I, Sorasio D, Manna E, Binello G, Strani G, et al. Hepatitis virus-related nephropathies. *G Ital Nefrol* 2012; 29(Suppl. 56): S62-S69.
23. Xu G, Huang T. Hepatitis B virus-associated glomerular nephritis in East Asia: progress and challenges. *Eur J Intern Med* 2011; 22: 161-6.
24. Fabrizi F, Martin P, Messa P. Hepatitis B and hepatitis C virus and chronic kidney disease. *Acta Gastroenterol Belg* 2010; 73: 465-71.
25. Pol S, Sogni P. Treatment of chronic hepatitis B: adherence and safety. *Gastroenterol Clin Biol* 2010; Suppl. 2: S142-S148.
26. Tsai M, Chen Y, Chien Y, Chen T, Hu T. Hepatitis B virus infection and renal transplantation. *World J Gastroenterol* 2010; 16: 3878-87.
27. Fabrizi F, Messa P, Basile C, Martin P. Hepatic disorders in chronic kidney disease. *Nat Rev Nephrol* 2010; 6: 395-403.
28. Chan T. Hepatitis B and renal disease. *Curr Hepat Rep* 2010; 9: 99-105.
29. Zhang Y, Zhou J, Yin X, Wang F. Treatment of hepatitis B virus-associated glomerulonephritis: a meta-analysis. *World J Gastroenterol* 2010; 16: 770-7.
30. Kes P, Slavicek J. Hepatitis B virus and chronic progressive kidney disease. *Acta Med Croatica* 2009; 63: 397-402.

31. Cacoub P, Terrier B. Hepatitis B-related autoimmune manifestations. *Rheum Dis Clin North Am* 2009; 35: 125-37.
32. Rotman Y, Brown T, Hoofnagle J. Evaluation of the patient with hepatitis B. *Hepatology* 2009; 49: S22-S27.
33. Cacoub P, Terrier B. Hepatitis B-related autoimmune manifestations. *Rheum Dis Clin North Am* 2009; 35: 125-37.
34. Liang T. Hepatitis B: the virus and disease. *Hepatology* 2009; 49: S13-S21.
35. Peters M. Special populations with hepatitis B virus infections. *Hepatology* 2009; 49: S146-S155.
36. Adeyi O. Vascular and glomerular manifestations of viral hepatitis B and C: a review. *Semin Diagn Pathol* 2009; 26: 116-21.
37. Liang T. Hepatitis B: the virus and disease. *Hepatology* 2009; 49: S13-S21.
38. Fabrizi F, Dixit V, Martin P. Meta-analysis: anti-viral therapy of hepatitis B virus-associated glomerulonephritis. *Aliment Pharmacol Ther* 2006; 24: 781-8.
39. Chabane N, Loghmanri H, Melki W, Hellara O, Safer L, Bdiou F, Saffar H. Chronic viral hepatitis and kidney failure. *Presse Med* 2008; 37: 665-78.
40. Akagi S, Sugiyama H, Makino H. Infection and kidney disease. *Nihon Rinsho* 2008; 66: 1794-8.
41. Lai A, Lai K. Viral nephropathy. *Nat Clin Pract Nephrol* 2006; 2: 254-62.
42. Izzedine H, Massard J, Poynard T, Deray G. Lamivudine and HBV-associated nephropathy. *Nephrol Dial Transplant* 2006; 21: 828-9.
43. Cacoub P, Saadoun D, Bourliere M, Khiri H, Martineau A, Benhamou Y, Varastet M, et al. Hepatitis B virus genotypes and extrahepatic manifestations. *J Hepatol* 2005; 43: 764-70.
44. Kanan N, Goffin E. Antiviral therapies for hepatitis-related glomerulonephritis. *Lancet* 2005; 366: 203.
45. Seedat Y. Glomerular disease in the tropics. *Semin Nephrol* 2003; 23: 12-20.
46. Wong F. Liver and kidney diseases. *Clin Liver Dis* 2002; 6: 981-1011.
47. Han S. Extra-hepatic manifestations of chronic hepatitis B. *Clin Liver Dis* 2004; 8: 403-18.
48. Fabrizi F, Martin P, Bunnapradist S. Treatment of chronic viral hepatitis in patients with renal disease. *Gastroenterol Clin North Am* 2004; 33: 655-70.
49. Fabrizi F, Bunnapradist S, Martin P. HBV infection in patients with end-stage renal disease. *Semin Liver Dis* 2004; 24: 63-70.
50. Bhimma R, Coovadia H. Hepatitis B virus-associated nephropathy. *Am J Nephrol* 2004; 24: 198-211.
51. Dando T, Plosker G. Adefovir dipivoxil: a review of its use in chronic hepatitis B. *Drugs* 2003; 63: 2215-34.
52. Wang N, Wu Z, Zhang Y, Guo M, Liao L. Role of hepatitis B virus infection in pathogenesis of IgA nephropathy. *World J Gastroenterol* 2003; 9: 2004-8.
53. di Belgiojoso G, Ferrario F, Landriani N. Virus-related glomerular diseases: histological and clinical aspects. *J Nephrol* 2002; 15: 469-79.
54. Lhotta K. Beyond hepatorenal syndrome: glomerulonephritis in patients with liver disease. *Semin Nephrol* 2002; 22: 302-8.
55. Trepo C, Guillemin L. Polyarteritis nodosa and extrahepatic manifestations of HBV infection: the case against autoimmune intervention in pathogenesis. *J Autoimmun* 2001; 16: 269-74.
56. Pyrsopoulos N, Reddy K. Extra-hepatic manifestations of chronic viral hepatitis. *Curr Gastroenterol Rep* 2001; 3: 71-8.
57. Krane N, Gaglio P. Viral hepatitis as a cause of renal disease. *South Med J* 1999; 92: 354-60.
58. Yamabe H. Hepatitis virus and glomerulonephritis. *Intern Med* 1998; 37: 800-1.
59. Praditpornsilpa K, Eiam-Ong S, Sitprija V. Hepatitis virus and kidney. *Singapore Med J* 1996; 37: 639-44.
60. Safadi R, Almog Y, Dranitzki-Elhalel M, Rosenmann E, Tur-Kaspa R. Glomerulonephritis associated with acute hepatitis B. *Am J Gastroenterol* 1996; 91: 138-9.
61. Pucillo L, Agnello V. Membranoproliferative glomerulonephritis associated with hepatitis B and hepatitis C viral infections: from viruslike particles in the cryoprecipitate to viral localization in paramesangial deposits, problematic investigations prone to artifacts. *Curr Opin Nephrol Hypertens* 1994; 3: 465-70.
62. Martin P, Friedman L. Chronic viral hepatitis and the management of chronic renal failure. *Kidney Int* 1995; 47: 1231-41.
63. Glasscock R. Secondary membranous glomerulonephritis. *Nephrol Dial Transplant* 1992; 7: 64-71.
64. Lai K, Lai F. Clinical features and the natural course of hepatitis B virus-related glomerulopathy in adults. *Kidney Int Suppl* 1991; 35: S40-S45.
65. Levy M, Chen N. Worldwide perspective of hepatitis B-associated glomerulonephritis in the 80s. *Kidney Int Suppl* 1991; 35: S24-S33.
66. Johnson R, Couser W. Hepatitis B infection and renal disease: clinical, immunopathogenetic and therapeutic considerations. *Kidney Int* 1990; 37: 663-76.
67. Ronco P, Verroust P, Morel-Maroger L. Viruses and glomerulonephritis. *Nephron* 1982; 31: 97-102.
68. Dienstag J. Hepatitis B as an immune complex disease. *Semin Liv Dis* 1981; 1: 45-57.
69. Levo Y. Extrahepatic manifestations of hepatitis B virus infection. *Isr J Med Sci* 1979; 15: 276-82.
70. Dienstag J. Immunopathogenesis of the extra-hepatic manifestations of hepatitis B virus infection. *Springer Semin Immunopathol* 1981; 3: 461-72.
71. McIntosh R, Carr R, Kohler P. Etiology, epidemiology, and pathogenesis of renal disease. *Pathobiol Annu* 1977; 7: 143-89.
72. Gocke D. Extrahepatic manifestations of viral hepatitis. *Am J Med Sci* 1975; 270: 49-52.
73. Howard R, Balfour H. Viral infections and kidney disease. *Min Med* 1975; 58: 809-12.

REPORTS REGARDING ACUTE KIDNEY INJURY / HBV (INCLUDING TRANSPLANT RECIPIENTS; ADULTS ONLY)

1. Huang Z, Lin C, Fang J, Wang N, Zhou R, Pan C. Acute kidney injury in hepatitis B-related acute-on-chronic liver failure without pre-existing liver cirrhosis. *Hepatol Int* 2015; 9: 416-23.
2. Wan Z, Wang J, You S, Liu H, Zhu B, Zang H, Li C, et al. Cystatin C is a biomarker for predicting acute kidney injury in patients with acute-on-chronic liver failure. *World J Gastroenterol* 2013; 19: 9432-8.

3. Tajima K, Kohno K, Shiono Y, Suzuki I, Kato Y, Hiroshima Y, Yamamoto M, et al. Acute kidney injury and inflammatory immune reconstitution syndrome in mixed genotype (A/E) hepatitis B virus co-infection in HIV associated lymphoma. *Int J Clin Exp Pathol* 2013; 6: 536-42.
4. Donataccio M, Dalle Ore G, Donataccio D. Acute renal failure following administration of hepatitis B immunoglobulins in liver transplantation. *Minerva Gastroenterol Dietol* 2009; 55: 501-4.
8. Rais-Jalali G, Sagheb M, Daniali F, Behzadi S, Roozbeh J, Nikeghbalian S, Bahador A, et al. Acute renal failure in the first 100 orthotopic liver transplant patients in south-eastern Iran. *Exp Clin Transplant* 2007; 5: 710-2.

REPORTS REGARDING CKD/HBV (NATIVE KIDNEYS; ADULTS ONLY)

1. Wang C, Ye Z, Zeng D, Xie F, Qu L, Zheng Z. Clinico-pathological features of cryoglobulinemic glomerulonephritis associated with HBV infection: a retrospective analysis of 8 cases in China. *Int J Clin Exp Pathol* 2015; 8(9): 10475-81. eCollection 2015.
2. Jiang W, Liu T, Dong H, Xu Y, Liu L, Guan G, Liu X. Relationship between serum DNA replication, clinico-pathological characteristics and prognosis of hepatitis B virus-associated glomerulonephritis with severe proteinuria by lamivudine plus adefovir dipivoxil combination therapy. *Bioned Environ Sci* 2015; 28: 206-13.
3. Xiong Q, Zhong Y, Hu Z, Yang Y. Successful treatment of occult hepatitis B virus infection related membranous nephropathy after entecavir therapy. *Acta Clin Belg* 2015; 70: 223-5.
4. Li D, Gao G, Jiang H, Tang Z, Zang G. Hepatitis B virus-associated glomerulonephritis in HBsAg serological-negative patients. *Eur J Gastroenterol Hepatol* 2015; 27(1): 65-9. doi: 10.1097/MEG.0000000000000236.
5. Qi X, Wang J, Chen L, Huang Y, Qin Y, Mao R, Zhang J. Impact of nucleos(t)ide analogue combination therapy on the estimated glomerular filtration rate in patients with chronic hepatitis B. *Medicine (Baltimore)* 2015; 94: e646.
6. Dogan Z, Sarikaya M, Ergul B, Filik L. Incidental kidney findings in ultrasonography: a hidden iceberg bottom for patients with chronic hepatitis B? *Bratisl Lek Listy* 2015; 116(2): 136.
7. Li D, Gao G, Jiang H, Tang Z, Yu Y, Zang G. Hepatitis B virus-associated glomerulonephritis in HBsAg serological-negative patients. *Eur J Gastroenterol Hepatol* 2015; 27(1): 65-9. doi: 10.1097/MEG.0000000000000236.
8. Yoo J, Lee J, Yoon J, Lee M, Lee D, Cho Y, Jang E, et al. Hepatitis B virus-related glomerulonephritis: not a predominant cause of proteinuria in Korean patients with chronic hepatitis B. *Gastroenterol Res Pract* 2015; 2015: doi: 10.1155/2015/126532. Epub 2015 Feb 18.
9. Qi X, Wang J, Mao R, et al. Impact of nucleos(t)ide analogues on the estimated glomerular filtration rate in patients with chronic hepatitis B: a prospective cohort study in China. *J Viral Hepat* 2015; 22: 46-54.
10. Das N, Bhattacharyya A, Paria B, Sarkar S. Study on assessment of renal function in chronic liver disease. *J Clin Diagn Res* 2015; 9: 0C09-12. doi: 10.7860/JCDR/2015/11423.5658. Epub 2015 Mar 1.
11. Mallet V, Schwarzsinger M, Vallet-Pichard A, Fontaine H, Corouge M, Sogni P, Pol S. Effect of nucleoside and nucleotide analogues on renal function in patients with chronic hepatitis B virus mono-infection. *Clin Gastroenterol Hepatol* 2015; 13(6): 1181-8.e1. doi: 10.1016/j.cgh.2014.11.021. Epub 2014 Nov 21.
12. Cholongitas E, Vasiliadis T, Goulis I, Fouzas I, Antoniadis N, Papanikolaou V, Akriviadis E. Telbivudine is associated with improvement of renal function in patients transplanted for HBV liver disease. *J Viral Hepat* 2015; 22(7): 574-80. doi: 10.1111/jvh.12362. Epub 2014 Nov 11.
13. Lin C, Chien RN, Yeh C, Hsu CW, Chang ML, Chen YC, Yeh CT. Significant reno-protective effect of telbivudine during pre-emptive antiviral therapy in advanced liver cancer patients receiving cisplatin-based chemotherapy: a case-control study. *Scand J Gastroenterol* 2014; 49(12): 1456-64. doi: 10.3109/00365521.2014.962604. Epub 2014 Oct 6.
14. Mweemba A, Zanolini A, Mulenga L, Emge D, Chi BH, Wandeler G, Vinikoor MJ. Chronic hepatitis B virus co-infection is associated with renal impairment among Zambian HIV-infected adults. *Clin Infect Dis* 2014; 59(12): 1757-60. doi: 10.1093/cid/ciu734. Epub 2014 Sep 16.
15. Fang J, Li W, Tan Z, Li D. Comparison of prednisolone and lamivudine combined therapy with prednisolone mono-therapy on carriers of hepatitis B virus with IgA nephropathy: a prospective cohort study. *Int Urol Nephrol* 2014; 46(1): 49-56. doi: 10.1007/s11255-013-0480-5. Epub 2013 Jun 12.
16. Hui D, Yan X, Wei J, Ruixia M, Guangiu G. Significance of mutations in hepatitis B virus X gene for the pathogenesis of HB-associated glomerulonephritis. *Acta Virol* 2014; 58: 278-81.
17. Liu Y, Fan R, Chen J, Zheng Z, Liao B, Liang X, Yin J, et al. Assessment of renal function and risk factors for renal impairment in patients with hepatitis B virus-related liver cirrhosis. *Nan Fang Yi Ke Da Xue Xue Bao* 2014; 34(4): 472-6. Chinese.
18. Viganò M, Martin P, Cappelletti M, Fabrizi F. HBV-associated cryoglobulinemic vasculitis: remission after antiviral therapy with entecavir. *Kidney Blood Press Res* 2014; 39: 65-73.
19. Banerjee T, Scherzer R, Powe N, Steffick D, Shahinian V, Saran R, Pavkov M, et al, for the Centers for Disease Control and Prevention Chronic Kidney Disease Surveillance Team. Race and other risk factors for incident proteinuria in a national cohort of HIV-infected veterans. *J Acquir Immune Defic Syndromes* 2014; 67(2): 145-52. doi: 10.1097/QAI.0000000000000285.
20. Du W, Zheng Z, Han S, Ma S, Chen S. HBV reactivation in an occult HBV infection patient treated with prednisone for nephrotic syndrome: case report and literature review. *BMC Infect Dis* 2013; 13: 394. doi: 10.1186/1471-2334-13-394.
21. Zhou Y, Zhu N, Wang X, Wang L, Gu L, Yuan W. The role of the toll-like receptor TLR4 in hepatitis B virus-associated glomerulonephritis. *Arch Virol* 2013; 158: 425-33.
22. Shah H, Patel C, Jhaveri K. Complete remission of hepatitis B virus-associated nephrotic syndrome from IgA nephropathy following peginterferon therapy. *Ren Fail* 2013; 35: 295-8.

23. Hsieh M, Lu P, Kuo M, Lin W, Lin C, Lai C, Tsai J, et al. Prevalence and associated factors with chronic kidney disease in human immunodeficiency virus-infected patients in Taiwan. *J Microbiol Immunol Infect* 2013; 1-7.
24. Kong D, Wu D, Wang T, Li T, Xu S, Chen F, Jin X, et al. Detection of viral antigens in renal tissue of glomerulonephritis patients without serological evidence of hepatitis B virus and hepatitis C virus infection. *Int J Infect Dis* 2013; 17(7): e535-8. doi: 10.1016/j.ijid.2013.01.017. Epub 2013 Mar 7.
25. Ganesan A, Krantz E, Huppler Hullsiek K, Riddle M, Weintrob A, Lalani T, Okulicz N, et al.; Infectious Disease Clinical Research Program HIV/STI Working Group. Determinants of incident chronic kidney disease and progression in a cohort of HIV-infected persons with unrestricted access to health care. *HIV Med* 2013; 14(2): 65-76. doi: 10.1111/j.1468-1293.2012.01036.x. Epub 2012 Jul 19.
26. Cao Y, Gong M, Han Y, Xie J, Xuemei L, Zhang L, Li Y, et al. Prevalence and risk factors for chronic kidney disease among HIV-infected antiretroviral therapy-naïve patients in Mainland China: a multicenter cross-sectional study. *Nephrology* 2013; 18: 307-12.
27. Bickel M, Marben W, Betz C, Khaykin P, Stephan C, Gute P, Haberl A, et al. End-stage renal disease and dialysis in HIV-positive patients: observations from a long-term cohort study with a follow-up of 22 years. *HIV Medicine* 2013; 14: 127-35.
28. Mou S, Li J, Yu Z, Wang Q, Ni Z. Keto acid-supplemented low-diet protein diet for treatment of adult patients with hepatitis B virus infection and chronic glomerulonephritis. *J Int Med Res* 2013; 41: 129-37.
29. Sun I, Hong Y, Park H, Choi S, Chung B, Park C, Yang C, et al. Clinical characteristics and treatment of patients with IgA nephropathy and hepatitis B surface antigen. *Ren Fail* 2013; 35: 446-51.
30. Mocroft A, Neuhaus J, Peters L, Ryom L, Bickel M, Grint D, Koirala J, et al; INSIGHT SMART Study Group. Hepatitis B and C co-infection are independent predictors of progressive kidney disease in HIV-positive, antiretroviral-treated adults. *PLoS One* 2012; 7: e40245.
31. Gish R, Clark M, Kane S, Shaw R, Mangahas M, Bagai S. Similar risk of renal events among patients treated with tenofovir or entecavir for chronic hepatitis B. *Clin Gastroenterol Hepatol* 2012; 10: 941-6.
32. Chen Y, Chang C, Chang C, Wang T, Wu C, Chen H. Is an estimated glomerular filtration rate better than creatinine to be incorporated into the end-stage liver disease score? *World J Hepatol* 2012; 4(11): 291-8. doi: 10.4254/wjh.v4.i11.291.
33. Li P, Wei R, Tang L, Wu J, Zhang X, Chen X. Clinical and pathological analysis of hepatitis B virus-related membranous nephropathy and idiopathic membranous nephropathy. *Clin Nephrol* 2012; 78: 456-64.
34. Zhang L, Meng H, Han X, Han C, Sun C, Ye F, Jin X. The relationship between HBV serum markers and the clinico-pathological characteristics of hepatitis B virus-associated glomerulonephritis in the northeastern Chinese population. *Virol J* 2012; 9: 200.
35. Shi C, Huang J, Liu X, Zeng X, Cheng C, Yin Q, Li M, et al. Diagnostic significance of hepatitis B viral antigens in patients with glomerulonephritis –associated hepatitis B virus infection. *Diagn Microbiol Infect Dis* 2012; 72: 156-60.
36. Sun I, Hong Y, Park H, Choi S, Chung B, Park C, Yang C, et al. Experience of antiviral therapy in hepatitis B-associated membranous nephropathy. *Korean J Intern Med* 2012; 27: 411-6.
37. Moon J, Lee S. Treatment of hepatitis B virus-associated membranous nephropathy: lamivudine era versus post-lamivudine era. *Korean J Intern Med* 2012; 27: 394-6.
38. Tsai M, Chen J, Fang Y, Yang A, Chang C. Membranous nephropathy induced by pegylated interferon alpha-2a therapy for chronic viral hepatitis B. *Clin Nephrol* 2012; 77: 496-500.
39. Gwak G, Lee C, Lee D, Huh W, Koh K, Kim Y. Clinical impact of the development of YMDD mutants in hepatitis B virus-associated glomerulonephritis. *Hepatogastroenterology* 2011; 58: 1291-5.
40. Sakai K, Morito N, Usui J, Hagiwara M, Hitawashi A, Fukuda K, Nanmoku T, et al. Focal segmental glomerulosclerosis as a complication of hepatitis B virus infection. *Nephrol Dial Transplant* 2011; 26: 371-3.
41. Zhuang Y, Wei L, Yu Y, Zeng L, Xiong X, Wu Z. The expression and significance of nephrin in hepatitis B virus-associated membranous nephropathy. *Zhonghua Nei Ke Za Zhi* 2011; 50: 766-90.
42. Fabrizi F, Viganò M, Banfi G, Martin P, Messa P, Lampertico P. HBV-related liver disease in renal insufficiency: successful antiviral therapy with entecavir. *Int J Artif Organs* 2011; 34: 1031-5.
43. Mauss S, Berger F, Filmann N, Hueppe D, Henke J, Hegener P, Athmann C, et al. Effect of HBV polymerase inhibitors on renal function in patients with chronic hepatitis B. *J Hepatol* 2011; 55: 1235-40.
44. Flandre P, Pugliese P, Cuzin L, Bagnis C, Tack I, Cabié A, Poizot-Martin I, et al, on behalf of the New AIDS Data Group. Risk factors of chronic kidney disease in HIV-infected patients. *J Am Soc Nephrol* 2011; 6: 1700-7.
45. Xu G, Duang Z, Wu X, Zou H, Fang X, Tu W. Treatment of hepatitis B virus-associated membranous nephropathy patients in Chinese: an open parallel controlled trial. *Clin Chem Lab Med* 2011; 49: 1077-8.
46. Numata A, Akimoto T, Toshima M, Iwazu Y, Otani N, Miki T, Sugase T, et al. Membranous nephropathy in an HIV-positive patient complicated with hepatitis B virus infection. *Clin Exp Nephrol* 2011; 15: 769-73.
47. Das P, Vivek V, Ford M, Kingdon E, Holt S. Hepatitis B virus related membranous glomerulonephritis and proteinuria treated with lamivudine and tenofovir. *BMJ Case Rep* 2011. pii: bcr0520114287. doi: 10.1136/bcr.05.2011.4287.
48. Yanagisawa N, Ando M, Ajisawa A, Imamura A, Suganuma A, Tsuchiya K, Nitta K. Clinical characteristics of kidney disease in Japanese HIV-infected patients. *Nephron Clin Pract* 2011; 118: c285-c291.
49. Wiegand J, Karlas T, Schiefke I, Krasselt U, Bock T, Mossner J, Tillmann H. Resistance management in chronic hepatitis C complicated by renal failure. *Clin Nephrol* 2010; 74: 53-8.
50. Enriquez R, Sirvent A, Andrada E, Escolano C, Rodriguez J, Millan I, Gutierrez F, et al. Cryoglobulinemic glomerulonephritis in chronic hepatitis B infection. *Ren Fail* 2010; 32: 518-22.

51. Li X, Tian J, Wu J, He Q, Li H, Han F, Li Q, et al. A comparison of a standard dose prednisone regimen and mycophenolate mofetil combined with a lower prednisone dose in Chinese adults with idiopathic nephrotic syndrome who were carriers of hepatitis B surface antigen: a prospective cohort study. *Clin Ther* 2009; 31(4): 741-50. doi: 10.1016/j.clinthera.2009.04.011
52. Agarwal S, Tiwari S. Hepatitis B virus associated focal and segmental glomerular sclerosis; reports of two cases and review of the literature. *Clin Exp Nephrol* 2009; 13(4): 373-7.
53. Mesquita M, Lasser L, Langlet P. Longterm (7-year) treatment with lamivudine monotherapy in HBV-associated glomerulonephritis. *Clin Nephrol* 2008; 70: 69-71.
54. Chuang T, Hung C, Huang S, Lee C. Complete remission of nephrotic syndrome of hepatitis B virus-associated membranous glomerulopathy after lamivudine monotherapy. *J Formos Med Assoc* 2007; 106: 869-73.
55. Wen Y, Chen M. Remission of hepatitis B virus-associated membrano-proliferative glomerulonephritis in a cirrhotic patient after lamivudine therapy. *Clin Nephrol* 2006; 65: 21-25.
56. Herbert J, Herberth Z, Abul-Ezz S, Kumar J, Gokden N. Hepatitis B infection as a possible cause of focal segmental glomerulosclerosis (FSGS). *Clin Nephrol* 2006; 65: 380-4.
57. Okuse C, Yotsuyanagi H, Yamada N, Ikeda H, Takahashi H, Suzuki M, Kondo S, et al. Successful treatment of hepatitis B virus-associated membranous nephropathy with lamivudine. *Clin Nephrol* 2006; 65: 53-6.
58. Panomsak S, Lewsuwan S, Eiam-Ong S, Kanjanabuch T. Hepatitis B virus-associated nephropathies in adults: a clinical study in Thailand. *J Med Assoc Thai* 2006; 89(Suppl. 2): S151-S156.
59. Di Marco V, De Lisi S, Li Vecchi M, Maringhini S, Barbaria F. Therapy with lamivudine and steroids in a patient with acute hepatitis B and rapidly progressive glomerulonephritis. *Kidney Int* 2006; 70: 1187-8.
60. Gan S, Devlin S, Scott-Douglas N, Burak K. Lamivudine for the treatment of membranous glomerulopathy secondary to chronic hepatitis B infection. *Can J Gastroenterol* 2005; 19: 625-9.
61. Dede F, Ayli D. Efficient treatment of crescentic glomerulonephritis associated with hepatitis B virus with lamivudine in a case referred with acute renal failure. *Nephrol Dial Transplant* 2006; 21: 3613-4.
62. Tang S, Lai F, Lui Y, Tang C, Kung N, Ho Y, Chan K, et al. Lamivudine in hepatitis B-associated membranous nephropathy. *Kidney Int* 2005; 68: 1750-8.
63. Guillevin L, Mahr A, Callard P, Godmer P, Pagnoux C, Leray E, Cohen P; French Vasculitis Study Group. Hepatitis B virus-associated polyarteritis nodosa: clinical characteristics, outcome, and impact of treatment in 115 patients. *Medicine (Baltimore)* 2005; 84: 313-22.
64. Sayarlioglu H, Erkoc R, Dogan E, Sayarlioglu M, Topal C. Mycophenolate mofetil use in hepatitis B associated membranous and membranoproliferative glomerulonephritis induces viral replication. *Ann Pharmacother* 2005; 39: 573.
65. Takaki A, Natsuka A, Satou C, Iwataa Y, Ikeda H, Fukushima M. A case of focal segmental glomerulosclerosis complicated with chronic hepatitis B and treated with steroid and LDL apheresis. *Nihon Jinzo Gakkai Shi* 2002; 44: 806-12.
66. Szczech L, Gange S, van der Horst C, Bartlett J, Young M, Cohen M, Anastos K, et al. Predictors of proteinuria and renal failure among women with HIV infection. *Kidney Int* 2002; 61: 195-202.
67. Smith A, Cartledge J, Griffiths M, Miller R. Response to hepatitis B induced membrano-proliferative glomerulonephritis to HAART. *Sex Transm Infect* 2001; 77: 302-3.
68. Kovacevic Z, Jovanovic D, Skataric V, Dimitrijevic J, Rarenovic V, Nozic D, Maksic D. Treatment of chronic viral hepatitis B in secondary membranoproliferative glomerulonephritis using recombinant alfa-2 interferon. *Vojnosanit Pregl* 2000; 57: 235-40.
69. Taskapan H, Oymak O, Dogukan A, Ozbakir O, Utas C. Transformation of hepatitis B virus-related membranous glomerulonephritis to crescentic form. *Clin Nephrol* 2000; 54: 161-3.
70. Kovacevic Z, Jovanovic D, Skataric D, Dimitrijevic J, Rarenovic V, Nozic D, Maksic D. Treatment of chronic viral hepatitis B in secondary membranoproliferative glomerulonephritis using recombinant alfa-2 interferon. *Vojnosanit Pregl* 2000; 57: 235-40.
71. Al-Wakeel J, Mitwalli A, Tarif N, Al-Mohaya S, Mzalik G, Khali M. Role of interferon-alpha in the treatment of primary glomerulonephritis. *Am J Kidney Dis* 1999; 33: 1142-6.
72. Abbas N, Pitt M, Green A, Solomon L. Successful treatment of hepatitis B virus-associated membranoproliferative glomerulonephritis with alpha interferon. *Nephrol Dial Transplant* 1999; 14: 1272-5.
73. Gonzalo A, Mampaso F, Barcena R, Gallego N, Ortuno J. Membranous nephropathy associated with hepatitis B virus infection: long-term clinical and histologic outcome. *Nephrol Dial Transplant* 1999; 14: 416-8.
74. Dhiman R, Kohli H, Das G, Joshi K, Chawla Y, Sakhuja V. Remission of HBV-related mesangioproliferative glomerulonephritis after interferon therapy. *Nephrol Dial Transplant* 1999; 14: 176-8.
75. Lopes Neto E, Lopes L, Kirsztajn G, Cruz C, Ferraz M, Silva A. Alpha-interferon therapy for HBV-related glomerulonephritis. *Sao Paulo Med J* 1998; 116: 1823-5.
76. Ohba S, Kimura K, Mise N, Konno Y, Suzuki N, Miyashita K, Tojo A, et al. Differential localization of s and e antigens in hepatitis B virus-associated glomerulonephritis. *Clin Nephrol* 1997; 48(1): 44-7.
77. Lin C, Lin C, Chang G, King C. Defect of cell-mediated immune response against hepatitis B virus: an indicator for pathogenesis of hepatitis B virus associated membranous nephropathy. *Nephron* 1997; 76: 178-85.
78. Willson R. Extrahepatic manifestations of chronic viral hepatitis. *Am J Gastroenterol* 1997; 92: 3-17.
79. Chung D, Yang W, Kim S, Yu E, Chung Y, Lee Y, Park J. Treatment of hepatitis B virus associated glomerulonephritis with recombinant human alpha interferon. *Am J Nephrol* 1997; 17(2): 112-7.
80. Paydas S, Seyrek N, Gonlusen G, Saglikler Y. The frequencies of hepatitis B virus markers and hepatitis C virus antibody in patients with glomerulonephritis. *Nephron* 1996; 74: 617-9.
81. Mouthon L, Deblois P, Sauvaget F, Meyrier A, Callard P, Guillevin L. Hepatitis B virus-related polyarteritis nodosa and membranous nephropathy. *Am J Nephrol* 1995; 15: 266-9.

82. Conjeevaram H, Hoofnagle J, Austin H, Park Y, Fried M, Di Bisceglie A. Long-term outcome of hepatitis B virus-related glomerulonephritis after therapy with interferon alfa. *Gastroenterology* 1995; 109: 540-6.
83. Shapiro R, Steinbrecher U, Magil A. Remission of nephrotic syndrome of HBV-associated membranous glomerulopathy following treatment with interferon. *Am J Nephrol* 1995; 15: 343-7.
84. Miranda-Guardiola F, Fernandez-Llama P, Badia J, Botey A, Estruch R, Darnell A, Rozman C, et al. Acute renal failure associated with alpha-interferon therapy for chronic hepatitis B. *Nephrol Dial Transplant* 1995; 10: 1441-3.
85. Lai F, Lai K, Tam J, Lui S, To K, Li P. Primary glomerulonephritis with detectable glomerular hepatitis B virus antigens. *Am J Surg Pathol* 1994; 18: 175-86.
86. Lidman C, Magnus L, Norder H, Weiland O. Interferon alpha-2b treatment in an HIV-infected patient with hepatitis B virus induced nephrotic syndrome. *Scand J Infect Dis* 1993; 25: 133-5.
87. Lai F, Li P, Suen M, Lui S, Lai K. Crescentic glomerulonephritis related to hepatitis B virus. *Mod Pathol* 1992; 5: 262-7.
88. Frankel A, Singer D, Winearls C, Evans D, Rees A, Pusey C. Type II essential mixed cryoglobulinemia: presentation, treatment and outcome in 13 patients. *Q J Med* 1992; 82: 101-24.
89. Li P, Lai F, Ho S, Wong K, Lui S, Lai K. Acute renal failure in hepatitis B virus-related membranous nephropathy with mesangiocapillary transition and crescentic transformation. *Am J Kidney Dis* 1992; 19: 76-80.
90. Schectman J, Kimmel P. Remission of hepatitis B-associated membranous glomerulonephritis in human immunodeficiency virus infection. *Am J Kidney Dis* 1991; 17: 716-8.
91. Lai K, Li P, Lui S, Au T, Tam J, Tong K, Lai F. Membranous nephropathy related to hepatitis B virus in adults. *N Engl J Med* 1991; 324: 1457-63.
92. Venkatesh V, Lieberman K, Kim D, Thung S, Dikman S, D'Agati V, Susin M, et al. Hepatitis - B associated glomerulonephritis: pathology, pathogenesis and clinical course. *Medicine (Baltimore)* 1990; 69: 200-16.
93. McMahon B, Alberts S, Wainwright R, Bulkow L, Lanier A. Hepatitis B related sequelae. Prospective study in 1400 hepatitis B surface antigen-positive Alaska native carriers. *Arch Intern Med* 1990; 150: 1051-4.
94. Lai K, Tam S, Lin H, Lai F. The therapeutic dilemma of the usage of corticosteroid in patients with membranous nephropathy and persistent hepatitis B virus surface antigenemia. *Nephron* 1990; 54: 12-7.
95. Lin C. Hepatitis B virus-associated membranous nephropathy: clinical features, immunological profiles, and outcome. *Nephron* 1990; 55: 37-44.
96. Rostoker G, Vidaud M, Wircin V, Meignan M, Lang P, Lagrue G, Goossens M, et al. HBV DNA and primary immune complex glomerulonephritis. *Nephron* 1990; 54: 101.
97. Lai K, Lai F, Tam J. IgA nephropathy associated with chronic hepatitis B virus infection in adults: the pathogenic role of HBsAg. *J Pathol* 1989; 157(4): 321-7.
98. Lai K, Li F, Tam S. IgA nephropathy associated with chronic hepatitis B virus infection in adults: the pathogenic role of HBsAg. *J Pathol* 1989; 157: 321-7.
99. Lee H, Koh H. Hepatitis B e antigen associated membranous nephropathy. *Nephron* 1989; 52: 356-9.
100. Lisker-Melman M, Webb D, Di Bisceglie A, Kassianides C, Martin P, Rustgi V, Waggoner J, et al. Glomerulonephritis caused by chronic hepatitis B virus infection: treatment with recombinant human alpha-interferon. *Ann Intern Med* 1989; 111(6): 479-83.
101. de Man R, Schalm S, van der Heijden A, ten Kate F, Wolff E, Heijtkink R. Improvement of hepatitis B-associated glomerulonephritis after antiviral combination therapy. *J Hepatol* 1989; 8: 367-72.
102. Furuse A, Hattori S, Terashima T, Karashima S, Matsuda I. Circulating immune complex in glomerulonephropathy associated with hepatitis B virus infection. *Nephron* 1982; 31: 212-8.
103. Lai F, Tam J, Li P, Lai K. Replication of hepatitis B virus with corticosteroid therapy in hepatitis B virus related membranous nephropathy. *Virchows Arch A Pathol Anat Histopathol* 1989; 414: 279-84.
104. Maggiore Q, Bartolomeo F, L'Abbate A, Misefari V. HBsAg glomerular deposits in glomerulonephritis: fact or artifact? *Kidney Int* 1981; 19: 579-86.
105. Obineche E, Awunor-Renner C. The role of hepatitis B surface antigen in acute glomerulonephritis in adults. *East Afr Med J* 1981; 58: 341-3.
106. Ito H, Hattori S, Matsuda I, Amamiya S, Haijano H, Yoshizawa H, Miyakawa Y, Mayumi M. Hepatitis B e antigen - mediated membranous glomerulonephritis. Correlation of ultrastructural changes with HBeAg in the serum and glomeruli. *Lab Invest* 1981; 44: 214-20.
107. Iida H, Nakamoto Y, Kobayashi K, Dohi K, Hattori N, Takeuchi J. Hepatic glomerulonephritis. Role of hepatitis B surface antigen (HBsAg). *Virchows Arch A Pathol Anat Histol* 1981; 392: 55-62.
108. Luciani J, Lemaire J, Bascoul S, Baldet P, Fourcade J, Barjon P. Extramembranous glomerulonephritis following hepatitis B. Simultaneous disappearance of serum virus antigen and glomerular lesions (author's transl). *Nouv Presse Med* 1980; 9: 2239-40.
109. O'Neill J. Hepatitis B infection in glomerulonephritis. *Br Med J (Clin Res Ed)* 1982; 284: 52.
110. Iida H, Izumino K, Asaka M, Kameyama T, Takata M, Mizumura Y, Sasayama S. Membranoproliferative glomerulonephritis associated with chronic hepatitis B in adults: pathogenetic role of HBsAg. *Am J Nephrol* 1987; 7: 319-24.
111. Takehoshi Y, Tanaka M, Miyakawa Y, Yoshizawa H, Takahashi K, Mayumi M. Free 'small' and IgG-associated 'large' hepatitis B e antigen in the serum and glomerular capillary walls of two patients with membranous glomerulonephritis. *N Engl J Med* 1979; 300: 814-9.
112. Thomas H, Potter B, Elias E, Sherlock S. Metabolism of the third component of complement in acute type B hepatitis, HB antigen positive glomerulonephritis, polyarteritis nodosum, and HBs antigen positive and negative chronic active liver disease. *Gastroenterology* 1979; 76: 673-9.
113. Levy M, Kleinknecht C, Peix A. Membranous nephropathy and HBsAg. *Lancet* 1979; 1: 113.
114. Nagy J, Bajtai G, Brasch H, Sule T, Ambrus M, Deak G, Hamori A. The role of hepatitis B surface antigen in the pathogenesis of glomerulopathies. *Clin Nephrol* 1979; 12: 109-16.

115. Knecht G, Chisari F. Reversibility of hepatitis B virus-induced glomerulonephritis and active chronic hepatitis after spontaneous clearance of serum hepatitis B surface antigen. *Gastroenterology* 1978; 75: 1152-6.
116. Hirschel B, Benusiglio L, Favre H, Chatelanat F, Humair L, Zubler R, Cruchard A. Glomerulonephritis associated with hepatitis B. report of a case and review of the literature. *Clin Nephrol* 1977; 8: 404-9.
117. Levo Y, Gorevic P, Kassab H, Tobias H, Franklin E. Liver involvement in the syndrome of mixed cryoglobulinemia. *Ann Intern Med* 1977; 87: 287-92.
118. Levo Y, Gorevic P, Kassab H, Zucker-Franklin D, Gigli I, Franklin E. Mixed cryoglobulinemia- an immune complex disease often associated with hepatitis B virus infection. *Trans Assoc Am Physicians* 1977; 90: 167-73.
119. Vargas R, Thomson K, Wilson D, Cameron J, Turner D, Gill D, Chantler C, et al. Mesangiocapillary glomerulonephritis with dense 'deposits' in the basement membrane of the kidney. *Clin Nephrol* 1976; 5: 73-82.
120. Blaker F, Hellwege H, Kramer U, Thoenes W. Perimembranous glomerulonephritis associated with hepatitis B antigen (author's transl). *Dtsch Med Wochenschr* 1975; 100: 790-4.
121. Nagy J, Par A, Bajtai G, Ambrus M, Deak G. Membranous glomerulonephritis induced by HB (Australia) antigen-antibody complexes. *Acta Morphol Acad Sci Hung* 1976; 24: 129-38.
122. [No authors listed]. The kidney in infectious diseases. *Perspect Nephrol Hypertens* 1976; 3: 203-21.
123. Murohashi T, Kaneko Y, Naganuma H, Obata N, Ebe T. Membranous nephritis observed in chronic hepatitis with positive HB antigen. *Nihon Jinzo Gakkai Shi* 1975; 17: 995-1004.
124. Shingu T, Hayashida K, Kashiwagi S, Kaji M. Hepatitis B antigen in children with nephritis (authors transl). *Fukuoka Igaku Zasshi* 1975; 66: 683-5.
125. Guardia J, Pedreira J, Martinez-Vazquez J, Vidal M, Vilardell M, Caralps A, Ferrer E, et al. Chronic glomerulonephritis with HB antigen. *Nouv Presse Med* 1975; 4: 2923-5.
126. Shingu T. Association between Australia antigen and glomerulonephritis (author's transl). *Rinsho Byori* 1975; 23: 680-2.
127. Baglin A, Domart M, Cassan P, Fritel D, Callard P, Barietty J. Nephrotic syndrome in a drug-addict. Possible role of hepatitis virus B. *Nouv Presse Med* 1975; 4: 1051.
128. Conte J, Fournier G. Letter: Australia antigen and glomerulonephritis. *Nouv Presse Med* 1975; 4: 429.
129. Hague R. Acute glomerulonephritis complicating Australia antigen-negative viral hepatitis. *Scand J Infect Dis* 1975; 7: 277-9.
130. Bajtai G, Ambrus M, Paal M, Nagy J, Deak G. Letter: Hepatitis-B antigenemia associated with progressive cirrhosis and membranous glomerulonephritis. *Lancet* 1975; 1: 102-3.
131. Stratta P, Camussi G, Ragni R, Vercellone A. Letter: Hepatitis B antigenemia associated with active chronic hepatitis and mesangioproliferative glomerulonephritis. *Lancet* 1975; 2: 179.
132. Razzak I, Bauer W, Itzel W. Hepatitis B antigenemia with panarteritis, diffuse proliferative glomerulitis and malignant hypertension. *Am J Gastroenterol* 1975; 63: 476-80.
133. Knieser M, Jenis E, Lowenthal D, Bancroft W, Burns W, Salhoub R. Pathogenesis of renal disease associated with viral hepatitis. *Arch Pathol* 1974; 97: 193-200.
134. Pedreira J, Guardia J, Vilardell M, Caralps A, Martinez-Vazquez J, Hernandez J, Bacardi R. Letter: HBsAg subtype and chronic glomerulonephritis. *Lancet* 1974; 2: 1513.
135. Myers B, Griffel B, Naveh D, Jankielowicz T, Klajman A. Membrano-proliferative glomerulonephritis associated with persistent viral hepatitis. *Am J Clin Pathol* 1973; 60: 222-8.
136. Vertun B, Bromberg-Sznek S, Krawczynski K. Glomerulonephritis with deposits of immune complexes containing Australia antigen in the glomeruli. *Pol Arch Med Wewn* 1973; 50: 1107-11.
137. Combes B, Shorey J, Barrera A, Stratsny P, Eigenbrodt E, Hull A, Carter N. Glomerulonephritis with deposition of Australia antigen-antibody complexes in glomerular basement membrane. *Lancet* 1971; 2: 234-7.

ANTIVIRAL MEDICATIONS TOWARDS HBV AND NEPHRO-TOXICITY (INCLUDING TRANSPLANT RECIPIENTS; ADULTS ONLY)

1. Shimizu M, Furusyo N, Ikezaki H, Ogawa E, Hayashi T, Ihara T, Harada Y, et al. Predictors of kidney tubular dysfunction induced by adefovir treatment for chronic hepatitis B. *World J Gastroenterol* 2015; 21(7): 2116-23. doi: 10.3748/wjg.v21.i7.2116
2. Maggi P, Montinaro V, Leone A, Fasano M, Volpe A, Bel-lacosa C, Grattagliano V, et al. Bone and kidney toxicity induced by nucleotide analogues in patients affected by HBV-related chronic hepatitis: a longitudinal study. *J Antimicrob Chemother* 2015; 70(4): 1150-4. doi: 10.1093/jac/dku502. Epub 2014 Dec 18.
3. Koklu S, Gulsen MT, Tuna Y, Koklu H, Yuksel O, Demir M, Guner R, et al; other collaborators. Differences in nephrotoxicity risk and renal effects among anti-viral therapies against hepatitis B. *Aliment Pharmacol Ther* 2015; 41(3): 310-9. doi: 10.1111/apt.13036. Epub 2014 Dec 4.
4. Magalhaes-Costa P, Matos L, Barreiro P, Chagas C. Fanconi syndrome and chronic renal failure in a chronic hepatitis B mono-infected patient treated with tenofovir. *Rev Esp Enferm Dig* 2015; 107: 512-4.
5. Jia H, Ding F, Chen J, Lian J, Zhang Y, Zeng L, Xiang D, et al. Early kidney injury during long-term adefovir dipivoxil therapy for chronic hepatitis B. *World J Gastroenterol* 2015; 21: 3657-32.
6. Mandala J, Nanda K, Wang M, De Baetselier I, Deese J, Lombard J, Owino F, et al. Liver and renal safety of tenofovir disoproxil fumarate in combination with emtricitabine among African women in a pre-exposure prophylaxis trial. *BMC Pharmacol Toxicol* 2014; 15: 77. doi: 10.1186/2050-6511-15-77.
7. Terasaka T, Ueta E, Ebara H, Waseda K, Hanayama Y, Takaki A, Kawabata T, et al. Long-term observation of osteomalacia caused by adefovir-induced Fanconi's syndrome. *Acta Med Okayama* 2014; 68(1): 53-6.
8. Lin Q, Pan F, Hong F, Pan C. Hypophosphatemic osteomalacia and renal Fanconi syndrome induced by adefovir in a patient with chronic hepatitis B. *Zhonghua Gan*

- Zang Bing Za Zhi 2014; 22(10): 779-80. Chinese. No abstract available.
9. Li H, Yuan X, Qiu L, Zhou Q, Xiao P. Efficacy of adefovir dipivoxil combined with a corticosteroid in 38 cases of nephrotic syndrome induced by hepatitis B virus-associated glomerulonephritis. *Ren Fail* 2014; 36(9): 1404-6. doi: 10.3109/0886022X.2014.952745.
 10. Shan C, Yin Q, Wu P. Efficacy and safety of tenofovir in a kidney transplant patient with chronic hepatitis B and nucleos(t)ide multidrug resistance: a case report. *J Med Case Rep* 2014; 8: 281. doi: 10.1186/1752-1947-8-281.
 11. Samarkos M, Theofanis V, Eliadi I, Vlachogiannakos J, Polyzos A. Tenofovir-associated Fanconi syndrome in a patient with chronic hepatitis B. *J Gastrointest Liver Dis* 2014; 23: 342.
 12. Viganò M, Brocchieri A, Spinetti A, Zaltron S, Mangia G, Facchetti F, Fugazza A, et al. Tenofovir-induced Fanconi syndrome in chronic hepatitis B mono-infected patients that reverse after tenofovir withdrawal. *J Clin Virol* 2014; 61(4): 600-3. doi: 10.1016/j.jcv.2014.09.016. Epub 2014 Oct 5.
 13. Ochi A, Ishimura E, Ichii M, Ohno Y, Nakatani S, Kobayashi I, Shima H, et al. Successful treatment of hepatitis B virus-associated membranous nephropathy with entecavir and immunosuppressive agents. *Nephrology (Carlton)* 2014; 19(9): 595-6. doi: 10.1111/nep.12292. No abstract available.
 14. Monteiro N, Branco M, Peres S, Borges F, Mansinho K. The impact of tenofovir disoproxil fumarate on kidney function: four-year data from the HIV-infected outpatient cohort. *J Int AIDS Soc* 2014; 17(Suppl. 3): 19565.
 15. Shan C, Yin G, Wu P. Efficacy and safety of tenofovir in a kidney transplant patient with chronic hepatitis B and nucleos(t)ide multidrug resistance: a case-report. *J Med Case Rep* 2014; 8: 281. doi: 10.1186/1752-1947-8-281.
 16. Iizuka Y, Sakai H, Kobayashi K, Iizuka K, Ito E, Mochizuki N, Asahina Y, et al. A case of chronic hepatitis B managed with continued adefovir despite treatment-related Fanconi syndrome and osteomalacia. *Nihon Shokakibyo Gakkai Zasshi* 2014; 111(8): 1618-23. Japanese.
 17. Jeong H, Lee J, Lee T, Lee J, Kim H, Heo M, Choi G, et al. Two cases of hypophosphatemic osteomalacia after long-term low dose adefovir therapy in chronic hepatitis B and literature review. *J Bone Metab* 2014; 21(1): 76-83. doi: 10.11005/jbm.2014.21.1.76. Epub 2014 Feb 28.
 18. Eguchi H, Tsuruta M, Tani J, Kuwahara R, Hiromatsu Y. Hypophosphatemic osteomalacia due to drug-induced Fanconi's syndrome associated with adefovir dipivoxil treatment for hepatitis B. *Intern Med* 2014; 53: 233-7.
 19. Tanaka M, Suzuki F, Seko Y, Hara T, Kawamura Y, Sezaki H, Hosaka T, et al. Renal dysfunction during long-term lamivudine plus adefovir dipivoxil therapy in patients with chronic hepatitis B. *J Gastroenterol* 2014; 49(3): 470-80. doi: 10.1007/s00535-013-0779-0. Epub 2013 Mar 26.
 20. Gracey D, Snelling P, McKenzie P, Strasser S. Tenofovir-associated Fanconi syndrome in patients with chronic hepatitis B mono-infection. *Antivir Ther* 2013; 18: 945-8.
 21. Hartono J, Aung M, Dan Y, Gowans M, Lim K, Lee Y, Lee G, Low H, et al. Resolution of adefovir-related nephrotoxicity by adefovir dose-reduction in patients with chronic hepatitis B. *Aliment Pharmacol Ther* 2013; 37(7): 710-9. doi: 10.1111/apt.12251. Epub 2013 Feb 21.
 22. Pradat P, Le Pogam M, Okon J, Trollet P, Mialhes P, Brochier C, Maynard M, et al. Evolution of glomerular filtration rate in HIV-infected HIV-HBV co-infected and HBV-infected patients receiving tenofovir disoproxil fumarate. *J Viral Hepat* 2013; 20(9): 650-7. doi: 10.1111/jvh.12088. Epub 2013 Mar 5.
 23. Wu C, Zhang H, Qian Y, Wang L, Gu X, Dai Z. Hypophosphatemic osteomalacia and renal Fanconi syndrome induced by low-dose adefovir dipivoxil: a case-report and literature review suggesting ethnic predisposition. *J Clin Pharm Ther* 2013; 38(4): 321-6. doi: 10.1111/jcpt.12050. Epub 2013 Apr 17.
 24. Shimohata H, Sakai S, Ogawa Y, Hirayama K, Kobayashi M. Osteomalacia due to Fanconi's syndrome and renal failure caused by long-term low-dose adefovir dipivoxil. *Clin Exp Nephrol* 2013; 17(1): 147-8.
 25. Law S, Li K, Ho Y. Acquired Fanconi syndrome associated with prolonged adefovir dipivoxil therapy in a chronic hepatitis B patient. *Am J Ther* 2013; 20: 713-6.
 26. Dai C, Zhu M, Wang B, Guo F, Zhang X, Song W, Zhu T, et al. Prolonged adefovir therapy associated Fanconi syndrome and interstitial nephritis in hepatitis B. *Intern Med* 2012; 42: 955-7.
 27. Mederacke I, Yurdaydin C, Grobhenning A, Erhardt A, Cakaloglu Y, Yalcin K, Gurel S, et al; Hep-Net/International Delta Hepatitis Study Group. Renal function during treatment with adefovir plus peginterferon alfa-2a vs. either drug alone in hepatitis B/D co-infection. *J Viral Hepat* 2012; 19(6): 387-95. doi: 10.1111/j.1365-2893.2011.01560.x. Epub 2011 Dec 19.
 28. Manolakopoulos S, Striki A, Papatheodoridis G. Letter: renal tubular dysfunction during nucleotide analogue therapy in chronic hepatitis B. *Aliment Pharmacol Ther* 2012; 36: 992-3.
 29. Kim Y, Cho H, Sinn D, Gwak G, Choi M, Koh K, Paik S, et al. Frequency and risk factors of renal impairment during long-term adefovir dipivoxil treatment in chronic hepatitis B patients. *J Gastroenterol Hepatol* 2012; 27: 306-12.
 30. Ebata S, Hashimoto S, Suzuki A, Ito M, Maoka T, Ishikawa Y, Mochizuchi T, et al. A case of adefovir-induced membranous nephropathy related to hepatitis B caused by lamivudine resistant virus after liver transplant due to Byler's disease. *Clin Exp Nephrol* 2012; 16: 805-10.
 31. Tanaka M, Setoguchi T, Ishidou Y, Arishima Y, Hirotsu M, Saitoh Y, Nakamura S, et al. Pathological femoral fractures due to osteomalacia associated with adefovir dipivoxil treatment for hepatitis B: a case report. *Diagn Pathol* 2012; 7: 108. doi: 10.1186/1746-1596-7-108.
 32. Gara N, Zhao X, Collins M, Chong W, Kleiner D, Jake Liang T, Ghany M, et al. Renal tubular dysfunction during long-term adefovir or tenofovir therapy in chronic hepatitis B. *Aliment Pharmacol Ther* 2012; 35: 1317-25.
 33. Li L, Dong G, Zhang X, Xie Y. Adefovir dipivoxil-induced Fanconi syndrome and hypophosphatemic osteomalacia associated with muscular weakness in a patient with chronic hepatitis B. *Nan Fang Yi ke Da Xue Xue Bao* 2011; 31: 1956.
 34. Das P, Vivek V, Ford M, Kindon E, Holt S. Hepatitis B virus related membranous glomerulonephritis and proteinuria treated with lamivudine and tenofovir. *BMJ Case Rep* 2011. pii: bcr0520114287. doi: 10.1136/bcr.05.2011.4287.

35. Fernandez-Fernandez B, Montoya-Ferrer A, Sanz AB, Sanchez-Niño MD, Izquierdo MC, Poveda J, Sainz-Prestel V, et al. Tenofovir nephrotoxicity: 2011 update. *AIDS Res Treat* 2011; 2011: 354908.
36. Law S, Li K, Ho K. Nephrotoxicity, including Fanconi's syndrome, caused by adefovir dipivoxil- is there a safe dose? *J Clin Pharm Ther* 2012; 37: 128-31.
37. Vigano' M, Lampertico P, Colombo M. Drug safety evaluation of adefovir in HBV infection. *Expert Opin Drug Saf* 2011; 10: 809-18.
38. Thurairajah P, Khanna A, Mutimer D. Add-on combination therapy with adefovir dipivoxil induces renal impairment in patients with lamivudine-refractory hepatitis B virus (J Viral Hepat 2010; 17: 123-139). *J Viral Hepat* 2011; 18: 820.
39. Shiffman M, Pol S, Rostaing L, Schiff E, Tabut D, Zeuzem S, Zong J, Frederick D, Rousseau F. Efficacy and pharmacokinetics of adefovir dipivoxil liquid suspension in patients with chronic hepatitis B and renal impairment. *J Clin Pharmacol* 2011; 51: 1293-1301.
40. Gluhovschi C, Gadalean F, Kaycsa A, Curescu M, Sporea I, Gluhovschi G, Petrica L, et al. Does the antiviral therapy of patients with chronic hepatitis exert nephrotoxic effects? *Immunopharmacol Immunotoxicol* 2011; 33(4): 744-50. doi: 10.3109/08923973.2010.551129. Epub 2011 Feb 14.
41. Girgis C, Wong T, Ngu M, Emmett L, Archer K, Chen R, Seibel M. Hypophosphataemic osteomalacia in patients on adefovir dipivoxil. *J Clin Gastroenterol* 2011; 45: 468-73.
42. Khedmat H, Taheri S. Associations of various histological morphologies of renal involvement in hepatitis B infection: analysis of 118 subjects. *Saudi J Kidney Transpl* 2010; 21: 964-6.
43. Rodriguez-Novoa S, Labarga P, D'Avolio A, Barreiro P, Albalade M, Vispo E, Solera C, et al. Impairment in kidney tubular function in patients receiving tenofovir is associated with higher tenofovir plasma concentrations. *AIDS* 2010; 24: 1064-6.
44. Tamori A, Enomoto M, Kobayashi S, Iwai S, Morikawa H, Sakaguchi H, Habu D, et al. Add-on combination therapy with adefovir dipivoxil induces renal impairment in patients with lamivudine-refractory hepatitis B virus. *J Viral Hepat* 2010; 17: 123-9.
45. Ha N, Ha N, Garcia R, Trinh H, Vu A, Nguyen H, Nguyen K, et al. Renal dysfunction in chronic hepatitis B patients treated with adefovir dipivoxil. *Hepatology* 2009; 50: 727-34.
46. Zhou X, Ke J, Sallas W, Farrell C, Mayers D, Pentikis H. Population pharmacokinetics of telbivudine and determination of dose adjustment for patients with renal impairment. *J Clin Pharmacol* 2009; 49: 725-34.
47. Ha N, Ha N, Garcia R, Trinh H, Vu A, Nguyen H, Nhuyen K, et al. Renal dysfunction in chronic hepatitis B patients treated with adefovir dipivoxil. *Hepatology* 2009; 50: 727-34.
48. Zhou X, Ke J, Sallas W, Farrell C, Mayers D, Pentikis H. Population pharmacokinetics of telbivudine and determination of dose adjustment for patients with renal impairment. *J Clin Pharmacol* 2009; 49: 725-34.
49. Izzedine H, Kheder-Elfekih R, Housset P, Sarkozy C, Brocheriois I, Deray G. Adefovir dipivoxil-induced acute tubular necrosis and Fanconi syndrome in a renal transplant patient. *AIDS* 2009; 23: 544-5.
50. Izzedine H, Hulot J, Launay-Vacher V, Marcellin P, Hadziyannis S, Currie G, Brosgart C, et al; Adefovir Dipivoxil International Study Group. Renal safety of adefovir dipivoxil in patients with chronic hepatitis B: two double-blind, randomized, placebo-controlled studies. *Kidney Int* 2004; 66: 1153-8.

LIVER/RENAL TRANSPLANT

1. Terzi A, Ozdemir B, Taslica F, Ozdemir F, Kirnap M, Haberal M. Clinicopathological study of kidney biopsies in patients before or after liver transplant. *Exp Clin Transplant* 2014; 12(Suppl. 1): 129-35.
2. Ebata S, Hashimoto S, Suzuki A, Ito M, Maoka T, Ishikawa Y, Mochizuchi T, et al. A case of adefovir-induced membranous nephropathy related to hepatitis B caused by lamivudine resistant virus after liver transplant due to Byler's disease. *Clin Exp Nephrol* 2012; 16: 805-10.
3. Toledo K, Perez-Saez M, Navarro M, Ortega R, Redondo M, Aguirre M, Rodriguez-Benot A, et al. Impact of recurrent glomerulonephritis on renal graft survival. *Transplant Proc* 2011; 43: 2182-6.
4. Yu T, Wen M, Wu M, Chen C, Cheng C, Li C, Shu K. Impact of posttransplantation glomerulonephritis on long-term outcome of kidney transplants: single-center 20 years of experience. *World J Surg* 2012; 36: 2923-30.
5. Fehr T, Riehle H, Nigg L, Gruter E, Ammann P, Renner E, Ambuhl P. Evaluation of hepatitis B and hepatitis C virus-infected renal allograft recipients with liver biopsy and noninvasive parameters. *Am J Kidney Dis* 2003; 42: 193-201.
6. Quan A, Portale A, Foster S, Lavine J. Resolution of hepatitis B virus-related membranoproliferative glomerulonephritis after orthotopic liver transplant. *Pediatr Nephrol* 1995; 9: 599-602.
7. Schwarz A, Krause P, Offermann G, Keller F. Impact of de novo membranous glomerulonephritis on the clinical course after kidney transplantation. *Transplantation* 1994; 58: 650-4.
8. Sonnabend W, Kistler G, Thiel G, Zollinger H, Bianchi L, Enderlin F, Gudat F, Krech U. Chronic focal glomerulonephritis and chronic persistent hepatitis following kidney transplantation. Detection of hepatitis B and Epstein-Barr virus antigen. *Schweiz Med Wochenschr* 1974; 104(35): 1205-17.